US11236045B2 - Substituted sulfoximine compounds - Google Patents

Substituted sulfoximine compounds Download PDF

Info

Publication number
US11236045B2
US11236045B2 US16/617,389 US201816617389A US11236045B2 US 11236045 B2 US11236045 B2 US 11236045B2 US 201816617389 A US201816617389 A US 201816617389A US 11236045 B2 US11236045 B2 US 11236045B2
Authority
US
United States
Prior art keywords
carbamoyl
hexahydro
indacen
cyano
benzenesulfonimidamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US16/617,389
Other versions
US20200140382A1 (en
Inventor
Rajiv Sharma
Pravin Iyer
Sameer Agarwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of US20200140382A1 publication Critical patent/US20200140382A1/en
Assigned to CADILA HEALTHCARE LIMITED reassignment CADILA HEALTHCARE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGARWAL, SAMEER, SHARMA, RAJIV, IYER, PRAVIN
Application granted granted Critical
Publication of US11236045B2 publication Critical patent/US11236045B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Definitions

  • the present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs.
  • the invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators.
  • NLR NOD-like receptor family
  • the present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1 ⁇ activity and interleukin-18 (IL-18) is implicated.
  • NLR protein NLRP3 is an intracellular signaling molecule that senses many pathogens, environmental and host-derived factors. (Wen., et. al., Immunity. 2013; 39:432-441). Activation of NLRP3 leads to binding with apoptosis associated speck-like protein containing a CARD (ASC). ASC in turn interacts with the cysteine protease caspase-1, forming a complex termed the inflammasome. This results in the activation of caspase-1, which cleaves the pro-inflammatory cytokines IL-1 ⁇ and IL-18 to their active forms and mediates a type of inflammatory cell death known as pyroptosis.
  • ASC apoptosis associated speck-like protein containing a CARD
  • PRRs intracellular pattern recognition receptors
  • NLRs include other NLR family members such as NLRP1 and NLRC4 and non-NLR PRRs such as the double-stranded DNA (dsDNA) sensors absent in melanoma 2 (AIM2) and interferon, gamma inducible protein 16 (IFI16).
  • dsDNA double-stranded DNA
  • AIM2 melanoma 2
  • IFI16 interferon, gamma inducible protein 16
  • NLRP3-dependent IL-1 ⁇ processing can also be activated by an indirect, non-canonical pathway downstream of caspase-1 (Lamkanfi, et. al., Cell. 2014; 157:1013-1022).
  • Inflammasome components such as NLRP3, ASC and caspase-1 are expressed in immune cells in the liver including Kupffer cells, infiltrating macrophages, hepatocytes, and hepatic stellate cells. Inflammasome activation is dependent on two successive signals.
  • Signal 1 is driven by TLR and IL-1R signaling, includes expression of component proteins including NLRP3, ASC, pro-caspase-1, pro-IL-1 ⁇ , and pro-IL-18.
  • Signal 2 is provided by danger signals (DAMPS) that during NASH development are mainly released by stressed or dying hepatocytes or via a “leaky” gut (PAMPs). This process leads to oligomerization of the inflammasome components and cleavage of pro-caspase-1, leading to the release of active pro-inflammatory cytokines.
  • DAMPS danger signals
  • the NLRP3 inflammasome acts as a key mediator of inflammatory responses through the activation of caspase-1 leading to processing and release of the pro-inflammatory cytokines interleukin-1 ⁇ (IL-1 ⁇ ) and interleukin-18 (IL-18).
  • the NLRP3 inflammasome is a component of the inflammatory process and its aberrant activation is pathogenic in inherited disorders such as the rare periodic fever syndrome, cryopyrin associated periodic syndromes (CAPS), Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, atherosclerosis, asthma, gouty arthritis, and inflammatory central nervous system (CNS) diseases.
  • CAPS cryopyrin associated periodic syndromes
  • TRAPS Tumor necrosis factor receptor-associated periodic syndrome
  • CNS central nervous system
  • Inflammation is an essential host response to infection and injury.
  • the regulation of the pro-inflammatory cytokine interleukin-1 ⁇ (IL-1 ⁇ ) which is central to host responses to infection, also causes tissue injury when activated inappropriately.
  • IL-1 ⁇ cytokine interleukin-1 ⁇
  • NLRP3 inflammasome activation plays a key role in each of the components including induction of pro-inflammatory signaling, hepatocellular injury and cell death, and activation of the hepatic stellate cells (HSC) that are responsible for collagen deposition and liver fibrosis.
  • HSC hepatic stellate cells
  • the transition from NAFLD to NASH associates with NLRP3-inflammasome activation and an increased expression of inflammasome-related components, including apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC), caspase-1 (CASP-1) and pannexin.
  • ASC carboxy-terminal CARD
  • CASP-1 caspase-1
  • pannexin pannexin
  • NLRP3 related diseases include biologic agents that target IL-1. These are the recombinant IL-1 receptor antagonist Anakinra, the neutralizing IL-1 ⁇ antibody Canakinumab and the soluble decoy IL-1 receptor Rilonacept.
  • novel heterocyclic compounds of general formula (I) which are NLRP3 Modulators for the prevention and treatment of disease states mediated by NLRP3 or conditions in which interleukin 1 ⁇ activity and interleukin-18 (IL-18) are implicated, including inflammation, Cryopyrin-associated periodic syndromes (CAPS), gouty arthritis, type 2 diabetes, atherosclerosis, and liver fibrosis. More particularly, embodiments of the present invention are useful as therapeutics in the treatment of a variety of pathological conditions including (but not limited to) lymphoma, auto-immune diseases, heteroimmune diseases, inflammatory diseases, cancer, and neurodegenerative diseases or conditions.
  • pathological conditions including (but not limited to) lymphoma, auto-immune diseases, heteroimmune diseases, inflammatory diseases, cancer, and neurodegenerative diseases or conditions.
  • the present invention discloses heterocyclic compounds as defined by the general formula (I) that are NLRP3 modulators for the prevention and treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1 ⁇ activity and interleukin-18 (IL-18) are implicated.
  • the compounds of the present invention are useful in the treatment of human or animal body, by inhibition of NLRP3.
  • the compounds of this invention are therefore suitable for the prevention and treatment of disease states mediated by NLRP3.
  • An embodiment of the present invention provides novel heterocyclic compounds represented by the general formula (I), their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutical compositions containing them or their mixtures thereof.
  • compositions containing compounds of the general formula (I), their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically acceptable salts, or their mixtures in combination with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions.
  • heterocyclic compounds of the present invention as NLRP3 modulators, by administering a therapeutically effective and non-toxic amount of compounds of general formula (I) or their pharmaceutically acceptable compositions to the mammals.
  • the present invention relates to the compounds of the general formula (I)
  • R 1 may represent one or more substituents selected from hydrogen, halogen, haloalkyl, cyano, optionally substituted groups selected from (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, aryl, heteroaryl, heterocyclyl, benzyl, thiol, mercapto alkyl, sulfur and its oxidized forms, C 1 -C 6 (thio-alkoxy), bridged or spiro ring system having optionally one or more than one heteroatoms;
  • ‘B’ is selected from optionally substituted (C 3 -C 6 )cycloalkyl, aryl, heteroaryl and heterocyclyl or the following ring system
  • X, Y, Z at each occurrence is independently selected from C, N, S, SO 2 , and O, which may be, wherever possible be optionally substituted;
  • R 2 at each occurrence independently represents hydrogen, halide, cyano, optionally substituted groups selected from (C 1 -C 6 )alkyl, (C 2 -C 6 ) alkenyl, (C 1 -C 6 )alkoxy (C 3 -C 6 )cycloalkyl, benzyl, aryl, heteroaryl, heterocyclyl, thiol, thioalkyl, thio-alkoxy sulfur and its oxidized forms, bridged or spiro ring system having optionally one or more than one heteroatoms;
  • R 3 at each occurrence independently represents hydroxyl, halogen, nitro, cyano, optionally substituted groups selected from (C 1 -C 10 )alkyl, (C 1 -C 10 )alkoxy, (C 3 -C 10 )cycloalkyl, (C 2 -C 10 ) alkenyl, (C 2 -C 10 )alkynyl, SO 2 (C 1 -C 6 )alkyl, benzyl, aryl, heteroaryl, heterocyclyl, thiol, thioalkyl, thio-alkoxy, (sulfur and its oxidized forms); in an embodiment, R 3 and A together with the atom to which they are attached may form a optionally substituted 5 to 7 membered heterocyclic ring system having optionally one or more than one heteroatoms; ‘m’ represents an integer from 1-5;
  • R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 at each occurrence are independently selected from hydrogen, halogen, cyano, amide, sulphonamide, acyl, hydroxyl, optionally substituted groups selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkoxy;
  • substitutions on them may be selected from hydrogen, hydroxy, cyano, halo, haloalkyl, haloalkyloxy, alkylthio (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 10 )cycloalkyl, C 1 -C 6 alkoxy, —COR 10 , —CSR 10 , C(O)OR 10 , C(O)—R 10 , —C(O)—NR 11 R 12 , —C(S)—NR 11 R 12 , —SO 2 R 10 group, wherein R 10 is independently selected from hydrogen, optionally substituted group selected from (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, (C 3 -C 7 )cycloalky
  • R 11 and R 12 is independently selected from hydrogen, optionally substituted group selected from (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, aryl or benzyl group;
  • the groups, radicals described above may be selected from:
  • Alkyl as well as other groups having the prefix “alk”, such as alkoxy and alkanoyl, means a carbon chain which may further be substituted with an oxygen atom as is well understood by a skilled artisan, which may further be either linear or branched, and combinations thereof, unless the carbon chain is defined otherwise.
  • alkyl group include but not are limited to methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert.-butyl, pentyl, hexyl etc.
  • the term alkyl also includes cycloalkyl groups, and combinations of linear or branched alkyl chains combined with cycloalkyl structures. When no number of carbon atoms is specified, C(1-6) is intended.
  • alkenyl means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched or combinations thereof, unless the carbon chain is defined otherwise.
  • alkenyl include but not limited to vinyl, allyl, isopropenyl, hexenyl, pentenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl etc.
  • the term alkenyl also includes cycloalkenyl groups and combinations of linear, branched and cyclic structures. When no number of carbon atoms is specified, C(2-6) is intended.
  • Alkynyl means carbon chains which contain at least one carbon-carbon triple bond, and which may be linear or branched or combinations thereof. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl etc. When no number of carbon atoms is specified, is intended.
  • the “thioalkyl” group used either alone or in combination with other radicals denotes an alkyl group, as defined above, attached to a group of formula —SR′, where R′ represents hydrogen, alkyl or aryl group, e.g. thiomethyl, methylthiomethyl, phenylthiomethyl and the like, which may be optionally substituted.
  • carbocycle or “carbocyclic residue” is intended to mean any stable monocyclic or bicyclic or tricyclic ring, any of which may be saturated, partially unsaturated, or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
  • carbocycle is intended to include, wherever applicable, the groups representing cycloalkyl
  • Cycloalkyl is the subset of alkyl and means saturated carbocyclic ring having a specified number of carbon atoms, preferably 3-6 carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl etc. A cycloalkyl group generally is monocyclic unless otherwise stated. Cycloalkyl groups are saturated unless and otherwise stated.
  • alkoxy refers to the straight or branched chain alkoxides of the number of carbon atoms specified.
  • Aryl means a mono- or polycyclic aromatic ring system containing carbon ring atoms.
  • the preferred aryls are monocyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls.
  • Heterocyclyl means a saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, further optionally including the oxidized forms of sulfur, namely SO & SO 2 .
  • heterocycles include tetrahydrofuran (THF), dihydrofuran, 1,4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazoline, imidazolidine, pyrrolidine, pyrroline, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane, thiomorpholine, etc.
  • THF tetrahydrofuran
  • dihydrofuran 1,4-dioxane
  • morpholine 1,4-dithiane
  • 1,4-dithiane piperazine
  • piperidine 1,3-dioxolane
  • imidazoline imidazolidine
  • pyrrolidine pyrroline
  • tetrahydropyran dihydropyran
  • heterocycloalkyl refers to a heterocyclic group as defined above connected to an alkyl group as defined above; “Heteroaryl” means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from O, S and N. Heteroaryls thus include heteroaryls fused to the other kinds of rings, such as aryls, cycloalkyls, and heterocycles that are not aromatic.
  • heteroaryl groups include; pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzothiadiazolyl, dihydrobenzofuranyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, cinnolinyl, phthalazinyl, quinazolin
  • haloalkyl means a alkyl structure in which at least one hydrogen is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another.
  • haloalkoxy is selected from suitable haloalkyl, as defined above, directly attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy, fluoroethoxy, chloroethoxy and the like;
  • the halogen atoms are not all the same as one another.
  • Aryloxyalkyl means an alkyl radical substituted with aryloxy group as defined herein.
  • Aryloxyaryl means an aryl radical substituted with aryloxy group as defined herein.
  • Aryloxyheteroaryl means a heteroaryl radical substituted with aryloxy group as defined herein.
  • Halo/Halogen refers to fluorine, chlorine, bromine, iodine. Chlorine and fluorine are generally preferred.
  • Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
  • substituted means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • “Pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of the basic residues.
  • Such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 1,2-ethanedisulfonic, 2-acetoxybenzoic, 2-hydroxyethanesulfonic, acetic, ascorbic, benzenesulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromie, hydrochloric, hydroiodide, hydroxymaleic, hydroxynaphthoic, ise
  • optionally substituted alkyl means either ‘alkyl’ or ‘substituted alkyl’. Further an optionally substituted group includes an unsubstituted group.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • Particularly useful compounds may be selected from but not limited to the following:
  • novel compounds of the present invention can be prepared using the reactions and techniques described below, together with conventional techniques known to those skilled in the art of organic synthesis, or variations thereon as appreciated by those skilled in the art.
  • the reactions can be performed in solvents appropriate to the reagents and materials employed and suitable for the transformations being affected. Preferred methods include, but not limited to those described below, where all symbols are as defined earlier unless and otherwise defined below.
  • Compound 2 can be prepared by variety of methods familiar to those skilled in art using a base like sodium hydroxide from commercially available sulfonyl chloride (1). Chlorination of 2 with reagents like thionyl chloride afforded 3. Compound 3 on treatment with ammonia under suitable conditions and appropriate solvents provided compound 4. Compound 4 on treatment with isocyanato derivative (5) under suitable conditions, in presence of base like butyl lithium and appropriate solvents provided compound of formula 6. Compound 6 was subjected to chlorination with suitable reagent under suitable conditions, base and solvent followed by reaction with optionally substituted amines to afford compounds of formula (I). Chiral separation of the compounds of formula (I) can be achieved using suitable chiral columns via techniques like HPLC; or by using suitable chiral reagents, by a person skilled in the art.
  • Example-1 Preparation of N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methyl benzene sulfonimidamide
  • reaction mixture was concentrated under reduced pressure, resulting residue was treated with water (30 mL) solid was collected by filtration, it was washed with water and hexane, then dried under reduced pressure in dessicator over P 2 O 5 to yield N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfinamide.
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfinamide (1.0 eq.) was taken in MeCN (10 mL) under N2 atm. Solid cyanamide (2.1 eq.), potassium tert-butoxide (2 eq.) and N-Chlorosuccinimide (1.2 eq.) were added subsequently. The resulted suspension was stirred further for 3 h at RT. Upon completion of starting material, reaction mixture was concentrated under reduced pressure. it was diluted with Ethyl Acetate (15 mL) and water, layers were separated, aq.
  • PG is selected from silyl groups like tert-butyldiphenylsilyl, tert-butyldimethylsilyl, trimethylsilyl or 9-Fluorenylmethyl carbamate, FMOC (Fluorenylmethyloxycarbonyl), t-Butyl carbamate, BOC; Benzyl carbamate, Acetamide, Benzylamine, p-Toluenesulfonamide.
  • A, B, R 1 , R 2 , and R 3 are as defined earlier.
  • Compound 7 can be prepared by using ammonia from commercially available sulfonyl chloride (1).
  • Example-2 Preparation of N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methyl benzene sulfonimidamide
  • N′-(tert-butyldimethylsilyl)-4-methylbenzenesulfon-imidamide 1.7 g, 5.98 mmol, 1.0 eq.
  • dry THF 25 mL
  • n-BuLi 2.87 mL, 2.5 M, 7.17 mmol, 1.2 eq.
  • Example 2 Using appropriate starting materials and suitable modifications of the process described in Example 2, including suitable addition and/or deletion of steps as may be necessary, well within the scope of a person skilled in the art, the following compounds were prepared in an analogues manner.
  • THP1 Trop-Horsfall Protein 1 monocytes were differentiated with PMA (Phorbol 12-myristate 13-acetate) (100 ng/ml) and incubated at 37° C. for 20 h in presence of 5% CO 2 . 2 ⁇ 10 5 differentiated cells were plated per well of 96 well tissue culture plates. The cells were primed using 500 ng/ml Lipopolysaccharide and incubating for 4 hrs under the same condition. The cells were then treated with various concentrations of the compounds for 30 min followed by treatment with 5 mM ATP for 1 hr.
  • PMA Phorbol 12-myristate 13-acetate
  • Example 1 Compound IC 50 (nM) Example 1 6.6 Example 17 12 Example 18 15 Example 19 23 Example 21 62 Example 22 13 Example 24 34 Example 25 5 Example 26 23 Example 27 27 Example 29 32 Example 30 28 Example 34 3 Example 35 13 Example 36 32 Example 37 5.6 Example 38 17 Example 39 3.3 Example 40 13 Example 41 4.8 Example 42 2.4 Example 43 27 Example 44 63 Example 45 23 Example 46 — Example 48 3.5 Example 51 19 Example 52 4.4 Example 53 45 Example 54 12 Example 55 27 Example 56 43 Example 58 38 Example 63 7.8 Example 64 7.7 Example 65 1.26 Example 66 4 In Vivo Efficacy Studies:
  • mice Female C57 mice (6-8 weeks) received intraperitoneal injection of 50 ⁇ g/mouse of lipopolysaccharide (LPS) in PBS. Animals were treated immediately with the test compounds or the vehicle. After 2 h of LPS injection, animals were administered with ATP at 12.5 mg/mouse dissolved in PBS via intraperitoneal route. After 30 minutes of ATP injection, serum was collected for IL-1 ⁇ estimation by ELISA.
  • LPS lipopolysaccharide
  • novel compounds of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.
  • a pharmaceutical composition comprising the compounds of the present invention may comprise a suitable binder, suitable bulking agent &/or diluent and any other suitable agents as may be necessary.
  • the pharmaceutical composition may be suitably coated with suitable coating agents.
  • the compounds of the present invention (I) are NLRP3 inhibitors and are useful in the treatment of disease states mediated by NLRP3, preferably diseases or conditions in which interleukin 1 ⁇ activity in which interleukin 1 ⁇ activity and interleukin-18 (IL-18) are implicated and related disorders.
  • the quantity of active component that is, the compounds of Formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
  • the compounds of the present invention may be used alone or in any combination with one or more other therapeutic agents which a skilled medical practitioner can easily identify.
  • Such other therapeutic agent may be selected depending on the type of disease being treated, the severity, other medications being taken by the patients etc.
  • one or more DMARDs may be used in combination with the compounds of the present invention.
  • compound of formula (I) of the present invention may be used in combination with one or more suitable pharmaceutically active agents selected from following therapeutic agents in any combination.
  • Inhibitors of interleukin-1 ⁇ e.g. rilonacept, canakinumab, and anakinra
  • immune-suppressants e.g., Methotrexate, mercaptopurine, cyclophosphamide
  • metabolic disorders drugs e.g., Methotrexate, mercaptopurine, cyclophosphamide
  • metabolic disorders drugs e.g., Methotrexate, mercaptopurine, cyclophosphamide
  • metabolic disorders drugs e.g., glucocorticoids, non-steroidal anti-inflammatory drugs, Cox-2 specific inhibitors, TNF- ⁇ binding proteins (eg., Infliximab, etanercept)
  • interferon-13 interferon
  • interleukin-2 antihistamines
  • beta-agonist beta
  • Non-Alcoholic Steato-Hepatitis NASH
  • fibrosis drugs anticancer antibiotics, hormones, Aromatase inhibitors, antibodies, cytokines, vaccines, drug conjugates, inhibitors of mitogen-activated protein kinase signaling (ex: BAY 43-9006), Syk inhibitors, mTOR inhibitors, antibodies (Rituxan), and BCR/ABL antagonist.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national stage completion application of PCT Application No. PCT/IB2018/054134, filed Jun. 8, 2018, and claims priority from India Application No. 201721020305, filed Jun. 9, 2017.
FIELD OF THE INVENTION
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.
BACKGROUND OF THE INVENTION
The NOD-like receptor family (NLR) protein NLRP3 is an intracellular signaling molecule that senses many pathogens, environmental and host-derived factors. (Wen., et. al., Immunity. 2013; 39:432-441). Activation of NLRP3 leads to binding with apoptosis associated speck-like protein containing a CARD (ASC). ASC in turn interacts with the cysteine protease caspase-1, forming a complex termed the inflammasome. This results in the activation of caspase-1, which cleaves the pro-inflammatory cytokines IL-1β and IL-18 to their active forms and mediates a type of inflammatory cell death known as pyroptosis. Other intracellular pattern recognition receptors (PRRs) are also capable of forming inflammasomes. These include other NLR family members such as NLRP1 and NLRC4 and non-NLR PRRs such as the double-stranded DNA (dsDNA) sensors absent in melanoma 2 (AIM2) and interferon, gamma inducible protein 16 (IFI16). (Latz, et. al., Nat Rev Immunol. 2013; 13:397-411) NLRP3-dependent IL-1β processing can also be activated by an indirect, non-canonical pathway downstream of caspase-1 (Lamkanfi, et. al., Cell. 2014; 157:1013-1022).
Inflammasome components such as NLRP3, ASC and caspase-1 are expressed in immune cells in the liver including Kupffer cells, infiltrating macrophages, hepatocytes, and hepatic stellate cells. Inflammasome activation is dependent on two successive signals. Signal 1 is driven by TLR and IL-1R signaling, includes expression of component proteins including NLRP3, ASC, pro-caspase-1, pro-IL-1β, and pro-IL-18. Signal 2 is provided by danger signals (DAMPS) that during NASH development are mainly released by stressed or dying hepatocytes or via a “leaky” gut (PAMPs). This process leads to oligomerization of the inflammasome components and cleavage of pro-caspase-1, leading to the release of active pro-inflammatory cytokines.
The NLRP3 inflammasome acts as a key mediator of inflammatory responses through the activation of caspase-1 leading to processing and release of the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). The NLRP3 inflammasome is a component of the inflammatory process and its aberrant activation is pathogenic in inherited disorders such as the rare periodic fever syndrome, cryopyrin associated periodic syndromes (CAPS), Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, atherosclerosis, asthma, gouty arthritis, and inflammatory central nervous system (CNS) diseases. (Masters, et. al., Annu Rev Immunol. 2009; 27:621-668; Strowig, et. al., Nature 2012, 481, 278-286; Guo, et. al., Nat. Med. 2015, 21, 677.)
Inflammation is an essential host response to infection and injury. The regulation of the pro-inflammatory cytokine interleukin-1β (IL-1β), which is central to host responses to infection, also causes tissue injury when activated inappropriately. (Dinarello, et. al., Nat. Rev. Drug Discovery 2012, 11, 633-652.) NLRP3 inflammasome activation plays a key role in each of the components including induction of pro-inflammatory signaling, hepatocellular injury and cell death, and activation of the hepatic stellate cells (HSC) that are responsible for collagen deposition and liver fibrosis. In particular, the transition from NAFLD to NASH associates with NLRP3-inflammasome activation and an increased expression of inflammasome-related components, including apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC), caspase-1 (CASP-1) and pannexin. (Mridha, et. al., Journal of Hepatology, 2017, 66 (5), 1037-1046)
Current treatments for NLRP3 related diseases include biologic agents that target IL-1. These are the recombinant IL-1 receptor antagonist Anakinra, the neutralizing IL-1β antibody Canakinumab and the soluble decoy IL-1 receptor Rilonacept.
Published patent applications WO98/32733, WO2001/019390, WO2014/190015, WO2016/123229 disclose certain WO/2016/131098 filed by The University Of Queensland disclosed sulfonylureas derivatives and related compounds as NLRP3 inflammasome inhibitors. WO2017/017469 filed by The University of Manchester, disclosed certain cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors for the treatment of diseases or conditions in which interleukin 1 β activity is implicated. Some of the recent patent applications such as WO2017031161, WO2017079352 disclosed certain class of compounds as NLRP3 inhibitors.
We herein disclose novel heterocyclic compounds of general formula (I) which are NLRP3 Modulators for the prevention and treatment of disease states mediated by NLRP3 or conditions in which interleukin 1β activity and interleukin-18 (IL-18) are implicated, including inflammation, Cryopyrin-associated periodic syndromes (CAPS), gouty arthritis, type 2 diabetes, atherosclerosis, and liver fibrosis. More particularly, embodiments of the present invention are useful as therapeutics in the treatment of a variety of pathological conditions including (but not limited to) lymphoma, auto-immune diseases, heteroimmune diseases, inflammatory diseases, cancer, and neurodegenerative diseases or conditions.
SUMMARY OF THE INVENTION
The present invention discloses heterocyclic compounds as defined by the general formula (I) that are NLRP3 modulators for the prevention and treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) are implicated. The compounds of the present invention are useful in the treatment of human or animal body, by inhibition of NLRP3. The compounds of this invention are therefore suitable for the prevention and treatment of disease states mediated by NLRP3.
EMBODIMENT(S) OF THE INVENTION
An embodiment of the present invention provides novel heterocyclic compounds represented by the general formula (I), their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutical compositions containing them or their mixtures thereof.
In a further embodiment of the present invention is provided pharmaceutical compositions containing compounds of the general formula (I), their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically acceptable salts, or their mixtures in combination with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions.
In a still further embodiment is provided the use of heterocyclic compounds of the present invention as NLRP3 modulators, by administering a therapeutically effective and non-toxic amount of compounds of general formula (I) or their pharmaceutically acceptable compositions to the mammals.
In a still further embodiment is provided a process for preparing the novel compounds of the present invention.
DESCRIPTION OF THE INVENTION
Accordingly, the present invention relates to the compounds of the general formula (I)
Figure US11236045-20220201-C00002
their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them wherein
    • ‘A’ is selected from unsubstituted or substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C6)cycloalkyl, aryl, heteroaryl and heterocyclyl groups having optionally one or more than one heteroatoms;
    • R1 at each occurrence independently represents hydrogen, halogen, haloalkyl, cyano, optionally substituted groups selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, (C3-C6)cycloalkyl, aryl, heteroaryl, heterocyclyl, benzyl, mercapto alkyl, sulfur and its oxidized form.
In an embodiment when A represents ring, R1 may represent one or more substituents selected from hydrogen, halogen, haloalkyl, cyano, optionally substituted groups selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, (C3-C6)cycloalkyl, aryl, heteroaryl, heterocyclyl, benzyl, thiol, mercapto alkyl, sulfur and its oxidized forms, C1-C6(thio-alkoxy), bridged or spiro ring system having optionally one or more than one heteroatoms;
‘B’ is selected from optionally substituted (C3-C6)cycloalkyl, aryl, heteroaryl and heterocyclyl or the following ring system
Figure US11236045-20220201-C00003
wherein X, Y, Z at each occurrence is independently selected from C, N, S, SO2, and O, which may be, wherever possible be optionally substituted;
n=0-3
R2 at each occurrence independently represents hydrogen, halide, cyano, optionally substituted groups selected from (C1-C6)alkyl, (C2-C6) alkenyl, (C1-C6)alkoxy (C3-C6)cycloalkyl, benzyl, aryl, heteroaryl, heterocyclyl, thiol, thioalkyl, thio-alkoxy sulfur and its oxidized forms, bridged or spiro ring system having optionally one or more than one heteroatoms;
R3 at each occurrence independently represents hydroxyl, halogen, nitro, cyano, optionally substituted groups selected from (C1-C10)alkyl, (C1-C10)alkoxy, (C3-C10)cycloalkyl, (C2-C10) alkenyl, (C2-C10)alkynyl, SO2(C1-C6)alkyl, benzyl, aryl, heteroaryl, heterocyclyl, thiol, thioalkyl, thio-alkoxy, (sulfur and its oxidized forms); in an embodiment, R3 and A together with the atom to which they are attached may form a optionally substituted 5 to 7 membered heterocyclic ring system having optionally one or more than one heteroatoms; ‘m’ represents an integer from 1-5;
Each of R4, R5, R6, R7, R8, and R9 at each occurrence are independently selected from hydrogen, halogen, cyano, amide, sulphonamide, acyl, hydroxyl, optionally substituted groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy; Alternatively each of R5 and R6, R7 and R8 or R8 and R9 wherever possible, together may form a 4 to 7 membered saturated or partially saturated ring containing from 0-2 additional heteroatoms selected from the group consisting of N, O, and S(O)p; p=1-2.
When any of above defined group is substituted the substitutions on them may be selected from hydrogen, hydroxy, cyano, halo, haloalkyl, haloalkyloxy, alkylthio (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, C1-C6 alkoxy, —COR10, —CSR10, C(O)OR10, C(O)—R10, —C(O)—NR11R12, —C(S)—NR11R12, —SO2R10 group, wherein R10 is independently selected from hydrogen, optionally substituted group selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C7)cycloalkyl, aryl, heteroaryl, heterocyclyl group;
R11 and R12 is independently selected from hydrogen, optionally substituted group selected from (C1-C6)alkyl, (C1-C6)alkoxy, aryl or benzyl group;
In a preferred embodiment, the groups, radicals described above may be selected from:
“Alkyl”, as well as other groups having the prefix “alk”, such as alkoxy and alkanoyl, means a carbon chain which may further be substituted with an oxygen atom as is well understood by a skilled artisan, which may further be either linear or branched, and combinations thereof, unless the carbon chain is defined otherwise. Examples of alkyl group include but not are limited to methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert.-butyl, pentyl, hexyl etc. Where the specified number of carbon atoms permits e.g. from C3-10, the term alkyl also includes cycloalkyl groups, and combinations of linear or branched alkyl chains combined with cycloalkyl structures. When no number of carbon atoms is specified, C(1-6) is intended.
“Alkenyl” means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched or combinations thereof, unless the carbon chain is defined otherwise. Examples of alkenyl include but not limited to vinyl, allyl, isopropenyl, hexenyl, pentenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl etc. Where the specified number of carbon atoms permits, e. g., from C5-10, the term alkenyl also includes cycloalkenyl groups and combinations of linear, branched and cyclic structures. When no number of carbon atoms is specified, C(2-6) is intended.
“Alkynyl” means carbon chains which contain at least one carbon-carbon triple bond, and which may be linear or branched or combinations thereof. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl etc. When no number of carbon atoms is specified, is intended.
the “thioalkyl” group used either alone or in combination with other radicals, denotes an alkyl group, as defined above, attached to a group of formula —SR′, where R′ represents hydrogen, alkyl or aryl group, e.g. thiomethyl, methylthiomethyl, phenylthiomethyl and the like, which may be optionally substituted.
As used herein, “carbocycle” or “carbocyclic residue” is intended to mean any stable monocyclic or bicyclic or tricyclic ring, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). In a broader perspective, the term carbocycle is intended to include, wherever applicable, the groups representing cycloalkyl, phenyl and other saturated, partially saturated or aromatic residues;
“Cycloalkyl” is the subset of alkyl and means saturated carbocyclic ring having a specified number of carbon atoms, preferably 3-6 carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl etc. A cycloalkyl group generally is monocyclic unless otherwise stated. Cycloalkyl groups are saturated unless and otherwise stated.
The “alkoxy” refers to the straight or branched chain alkoxides of the number of carbon atoms specified.
“Aryl” means a mono- or polycyclic aromatic ring system containing carbon ring atoms. The preferred aryls are monocyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls.
“Heterocyclyl” means a saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, further optionally including the oxidized forms of sulfur, namely SO & SO2. Examples of heterocycles include tetrahydrofuran (THF), dihydrofuran, 1,4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazoline, imidazolidine, pyrrolidine, pyrroline, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane, thiomorpholine, etc. The term “heterocycloalkyl” refers to a heterocyclic group as defined above connected to an alkyl group as defined above; “Heteroaryl” means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from O, S and N. Heteroaryls thus include heteroaryls fused to the other kinds of rings, such as aryls, cycloalkyls, and heterocycles that are not aromatic. Examples of heteroaryl groups include; pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzothiadiazolyl, dihydrobenzofuranyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, cinnolinyl, phthalazinyl, quinazolinyl, napthyridinyl, carbazolyl, benzodioxolyl, quinoxalinyl, purinyl, furazanyl, isobenzylfuranyl, benzimidazolyl, benzofuranyl, benzothienyl, quinolyl, indolyl, isoquinolyl, dibenzofuranyl etc. For heterocyclyl; and heteroaryl groups, rings and ring systems containing from 3-15 carbon atoms are included, forming 1-3 rings.
The term “haloalkyl” means a alkyl structure in which at least one hydrogen is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another.
the “haloalkoxy” group is selected from suitable haloalkyl, as defined above, directly attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy, fluoroethoxy, chloroethoxy and the like;
In certain other embodiment in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are not all the same as one another.
“Aryloxyalkyl” means an alkyl radical substituted with aryloxy group as defined herein.
“Aryloxyaryl” means an aryl radical substituted with aryloxy group as defined herein.
“Aryloxyheteroaryl” means a heteroaryl radical substituted with aryloxy group as defined herein.
“Halo/Halogen” refers to fluorine, chlorine, bromine, iodine. Chlorine and fluorine are generally preferred.
Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.
The term “substituted,” as used herein, means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. The term “substituted,” as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
“Pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of the basic residues. Such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 1,2-ethanedisulfonic, 2-acetoxybenzoic, 2-hydroxyethanesulfonic, acetic, ascorbic, benzenesulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromie, hydrochloric, hydroiodide, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, -lauryl sulfonic, maleic, malic, mandelic, methanesulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicyclic, stearic, subacetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, and toluenesulfonic.
The term ‘optional’ or ‘optionally’ means that the subsequent described event or circumstance may or may not occur, and the description includes instances where the event or circumstance occur and instances in which it does not. For example, optionally substituted alkyl’ means either ‘alkyl’ or ‘substituted alkyl’. Further an optionally substituted group includes an unsubstituted group.
Unless otherwise stated in the specification, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
Particularly useful compounds may be selected from but not limited to the following:
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzene sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzene sulfonimidamide;
  • N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methylbenzenesulfonimidamide;
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
  • N-((2,6-diisopropylphenyl)carbamoyl)-4-methylbenzenesulfonimidamide;
  • N-((2,6-diisopropylphenyl)carbamoyl)-4-methyl-N′-(2,2,2-trifluoroethyl)benzenesulfonimidamide;
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(2,2,2-trifluoroethyl)-benzenesulfonimidamide;
  • N-((2,6-diisopropylphenyl)carbamoyl)-N′-methoxy-4-methylbenzenesulfonimidamide;
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-isopropyl-4-methylbenzenesulfonimidamide;
  • N-((2,6-diisopropylphenyl)carbamoyl)-N′-isopropyl-4-methylbenzenesulfonimidamide;
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-methoxy-4-methylbenzenesulfonimidamide;
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′,4-dimethylbenzenesulfonimidamide;
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(1H-pyrazol-5-yl)benzenesulfonimidamide;
  • N′-(4-fluorophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
  • N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(pyridin-2-yl)benzenesulfonimidamide;
  • 4-acetyl-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-nitrobenzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methoxybenzenesulfonimidamide;
  • N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methoxybenzenesulfonimidamide;
  • N′-cyano-4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)(p-tolyl)-16-sulfanylidene)-methanesulfonamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxypyridine-3-sulfonimidamide;
  • N′-cyano-3-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
  • 4-chloro-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • 4-bromo-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • 4-(benzyloxy)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(trifluoromethyl)-benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-2-sulfonimidamide;
  • Ethyl ((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)(p-tolyl)-λ6-sulfaneylidene)-carbamate;
  • N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)-(p-tolyl)-λ6-sulfaneylidene)-acetamide;
  • N′-carbamoyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(3-hydroxyoxetan-3-yl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(prop-1-en-2-yl)furan-2-sulfonimidamide;
  • 5-bromo-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiophene-2-sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methoxybenzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonimidamide
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)thiophene-2-sulfonimidamide;
  • N′-cyano-2-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methylbenzenesulfonimidamide;
  • N′-cyano-3-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
  • N′-cyano-3,5-difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N′-cyano-2,4-difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(trifluoromethoxy)-benzenesulfonimidamide;
  • N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-phenylmethanesulfonimidamide;
  • N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(3-(2-hydroxypropan-2-yl)phenyl)(oxo)-16-sulfaneylidene)methanesulfonamide;
  • N′-cyano-N-((1,2,3,6,7,8-hexahydro-as-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiophene-2-sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,4-dimethoxybenzene-sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methylpyridine-2-sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methylpyridine-2-sulfonimidamide;
  • N′,3-dicyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzene-sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-3-sulfonimidamide
  • N′,4-dicyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-4-sulfonimidamide;
  • N′-cyano-3-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)quinoline-8-sulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-morpholinobenzene sulfonimidamide;
  • N-(3-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl) phenyl) acetamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-morpholinobenzene sulfonimidamide;
  • N′-cyano-4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
  • N′-cyano-2-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
  • N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)pyridine-3-sulfonimidamide;
  • N′-cyano-1-(4-cyanophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-methanesulfonimidamide;
  • 1-(4-cyanophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonimidamide;
  • N′-cyano-3-(2-hydroxypropan-2-yl)-N-((3-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-benzenesulfonimidamide.
or pharmaceutically acceptable salts of any of the compounds above.
Following is a list of abbreviations used in the description of the preparation of the compounds of the present invention:
bs: broad singlet
CDCl3: Deuterated chloroform
CHCl3: Chloroform
d: doublet
dd: doublet of doublet
dt: doublet of triplet
DCM: Dichloromethane
DMAC: N,N-(Dimethylacetamide)
DMAP: 4-(Dimethylamino) pyridine
DMF: N,N-Dimethyl formamide
DMSO: Dimethyl sulfoxide
EDTA: Ethylenediaminetertraacetic acid
EtOAc: Ethyl acetate
EtOH: Ethanol
HCl(g): Hydrogen chloride (gas)
K2CO3: Potassium carbonate
MeOH: Methanol
m: multiplet
mmol: millimoles
μg: microgram
MS: Mass spectrum
Na2CO3: Sodium carbonate
ng: nanogram
NIS: N-iodosuccinimide
1H NMR: Proton nuclear magnetic resonance
POCI3: Phosphorylchloride
s: singlet
t: Triplet
td: triplet of doublet
THF: Tetrahydrofuran
TLC: Thin layer chromatography
RT: room temperature
N2: Nitrogen
PMA = Phorbol 12-myristate 13-acetate
IL1β: Interleukin 1 beta
TNF α: Tumor necrosis factor alpha
DAMP: damage-associated molecular pattern;
PAMP: pathogen-associated molecular pattern;
TLR: Toll-like receptor.

General Process for Preparation
The novel compounds of the present invention can be prepared using the reactions and techniques described below, together with conventional techniques known to those skilled in the art of organic synthesis, or variations thereon as appreciated by those skilled in the art.
The reactions can be performed in solvents appropriate to the reagents and materials employed and suitable for the transformations being affected. Preferred methods include, but not limited to those described below, where all symbols are as defined earlier unless and otherwise defined below.
The compounds of the general formula (I) can be prepared as described in schemes below along with suitable modifications/variations which are well within the scope of a person skilled in the art.
Figure US11236045-20220201-C00004
Wherein A, B, R1, R2, and R3, are as defined earlier. Compound 2 can be prepared by variety of methods familiar to those skilled in art using a base like sodium hydroxide from commercially available sulfonyl chloride (1). Chlorination of 2 with reagents like thionyl chloride afforded 3. Compound 3 on treatment with ammonia under suitable conditions and appropriate solvents provided compound 4. Compound 4 on treatment with isocyanato derivative (5) under suitable conditions, in presence of base like butyl lithium and appropriate solvents provided compound of formula 6. Compound 6 was subjected to chlorination with suitable reagent under suitable conditions, base and solvent followed by reaction with optionally substituted amines to afford compounds of formula (I). Chiral separation of the compounds of formula (I) can be achieved using suitable chiral columns via techniques like HPLC; or by using suitable chiral reagents, by a person skilled in the art.
The invention is further illustrated by the following non-limiting examples which describe the preferred way of carrying out the present invention. These are provided without limiting the scope of the present invention in any way.
1H NMR spectral data given in the examples (vide infra) are recorded using a 400 MHz spectrometer (Bruker AVANCE-400) and reported in 6 scale. Until and otherwise mentioned the solvent used for NMR is CDCl3 using TMS as the internal standard.
Example-1: Preparation of N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methyl benzene sulfonimidamide Intermediate-1: Preparation 4-methylbenzenesulfinic Acid
Figure US11236045-20220201-C00005
Sodium sulfite (12.64 g, 100 mmol) was dissolved in water (50 mL) at room temperature; it was heated to 65° C. temp. 10 M solution of NaOH (7.22 g, 181 mmol) was added drop wise. At the same time p-toluenesulfonyl chloride (15.3 g, 80 mmol) was added portion wise. After the addition the reaction mixture was heated to 70° C. for 3 hours. After completion of starting material, hot solution was filtered and the filtrate was kept the fridge for 17 hours. Solid was ppt. out, filtered it. Then solid was dissolved in water (120 mL) and cooled to 0° C. temp., acidified with conc. HCl. stirred for 1 hour. and solid was filtered off, washed it with cold water (5 mL×3) and dried under desiccator over P2O5 to yield 4-methylbenzenesulfinic acid (8.0 g, 51.2 mmol, 63.8% yield)
1H NMR (400 MHz, CDCl3): δ=7.63 (d, 2H), 7.38 (d, 2H), 2.42 (s, 3H); MS (ESI): m/z (%)=154.4 (100%) (M−H)−.
Intermediate 2: Preparation of 4-methylbenzene-1-sulfinic chloride
Figure US11236045-20220201-C00006
4-methylbenzenesulfinic acid (10.0 g, 64.0 mmol) was taken in ether (50 mL), slurry was cooled to 0° C. and added thionyl chloride (18.69 ml, 256 mmol) drop wise. After the addition was completed, ice bath was removed and reaction mixture was heated to 40° C. for 4 hours. Upon completion of starting material, reaction mixture was concentrated under reduced pressure to obtain crude 4-methylbenzene-1-sulfinic chloride (11.18 g, 64.0 mmol, 100% yield). It was directly used in the next step without further purification.
Intermediate 3 Step 1: Preparation of 4-methylbenzenesulfinamide
Figure US11236045-20220201-C00007
4-methylbenzene-1-sulfinic chloride (11 g, 63.0 mmol) was dissolved in ether (50 mL), it was cooled to 0° C. and ammonia gas was purged for 45 min. Upon completion of starting material, reaction mixture was concentrated under reduced pressure. Then into it water was added, solid was filtered off and washed with water. The obtained solid was dried under reduced pressure in dessicator over P2O5 to yield 4-methylbenzenesulfinamide (7.6 g, 49.0 mmol, 78% yield)
1H NMR (400 MHz, CDCl3): δ=7.65 (d, 2H), 7.33 (d, 2H), 4.29 (s, 2H), 2.43 (s, 3H); MS (ESI): m/z (%)=155.33 (100%) (M+H)+
Intermediate 4 Preparation of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfinamide
Figure US11236045-20220201-C00008
4-methylbenzenesulfinamide (1 eq.) was dissolved in THF (20 mL) under N2 atm. it was cooled to −78° C. and drop wise added n-butyl lithium (1.2 eq), after the addition solution was stirred for 30 min. at −78° C. temp. Then bath was removed and reaction mixture was stirred for 30 min. at RT. Then 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (1.2 eq.) was added drop wise at RT. Solid was ppt. then reaction mixture was further stirred for 4 h at RT. Upon completion of starting material, reaction mixture was concentrated under reduced pressure, resulting residue was treated with water (30 mL) solid was collected by filtration, it was washed with water and hexane, then dried under reduced pressure in dessicator over P2O5 to yield N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfinamide.
Compound-1 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzene sulfonimidamide
Figure US11236045-20220201-C00009
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfinamide (1.0 eq.) was taken in MeCN (10 mL) under N2 atm. Solid cyanamide (2.1 eq.), potassium tert-butoxide (2 eq.) and N-Chlorosuccinimide (1.2 eq.) were added subsequently. The resulted suspension was stirred further for 3 h at RT. Upon completion of starting material, reaction mixture was concentrated under reduced pressure. it was diluted with Ethyl Acetate (15 mL) and water, layers were separated, aq. layer was back extracted with Ethyl Acetate (15 mL×4), all org. layer was combined and washed with water (15 mL), brine (15 mL), dried it over Na2SO4 and conc. under reduced pressure at 45° C. to yield crude product, which was purified by preparative HPLC to afford N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzene sulfonimidamide.
1H NMR (400 MHz, DMSO-d6): δ=7.91 (s, 1H), 7.65 (d, J=8.0 Hz, 2H), 7.27 (d, J=8.0 Hz, 2H), 6.78 (s, 1H), 2.75-2.67 (m, 4H), 2.65-2.56 (m, 4H), 2.34 (s, 3H), 1.92-1.83 (m, 4H); MS (ESI): m/z (%)=395.10 (100%) (M+H)+, 393.15 (100%) (M+H)
Alternatively, the compounds of the general formula (I) can be prepared as described in schemes below along with suitable modifications/variations which are well within the scope of a person skilled in the art.
Figure US11236045-20220201-C00010
Wherein PG is selected from silyl groups like tert-butyldiphenylsilyl, tert-butyldimethylsilyl, trimethylsilyl or 9-Fluorenylmethyl carbamate, FMOC (Fluorenylmethyloxycarbonyl), t-Butyl carbamate, BOC; Benzyl carbamate, Acetamide, Benzylamine, p-Toluenesulfonamide. A, B, R1, R2, and R3, are as defined earlier. Compound 7 can be prepared by using ammonia from commercially available sulfonyl chloride (1). Protection of amine group of 7 with suitable protecting groups like substituted silyl chlorides afforded 8. Compound 8 on treatment with triphenyl phosphine and dichloroethane under suitable conditions and appropriate solvents provide compound of compound 9. Compound 9 on treatment with isocyanato derivative (5) under suitable conditions, base like butyl lithium and appropriate solvents yielded compound of formula 10. Compound 10 was subjected to the deprotection with suitable reagent under suitable conditions, followed by reaction with optionally substituted halides provide compounds of formula (I). Chiral separation of the compounds of formula (I) can be achieved using suitable chiral columns via techniques like HPLC; or by using suitable chiral reagents, by a person skilled in the art.
The invention is further illustrated by the following non-limiting examples which describe the preferred way of carrying out the present invention. These are provided without limiting the scope of the present invention in any way.
Example-2: Preparation of N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methyl benzene sulfonimidamide Intermediate-1: Preparation N-(tert-butyldimethylsilyl)-4-methylbenzenesulfonamide
Figure US11236045-20220201-C00011
4-methylbenzenesulfonamide (10.0 g, 58.4 mmol, 1 eq.) was taken in THF (50 mL), and added triethyl amine (17.41 mL, 128 mmol, 2.2 eq.) drop wise at 0° C., further a solution of tert-butylchlorodimethylsilane (11.0 g, 73 mmol, 1.25 eq.) in toluene (10 mL) was added. After the addition completed, ice bath was removed and reaction mixture was heated to 50° C. for 16 h. Upon completion of starting material, reaction mixture was concentrated under reduced pressure. Subsequently it was diluted with EA (100 mL) and water, layers were separated, aq. layer was back extracted with EA (50 mL×4), all org. layer was combined and washed with water (50 mL), brine (50 mL), dried over Na2SO4 and conc. under reduced pressure at 45° C. to yield crude product, which was purified by column chromatography to afford N-(tert-butyldimethylsilyl)-4-methylbenzenesulfonamide (12 g, 72% yield)
1H NMR (DMSO-d6, 400 MHz) δ ppm: 7.69 (d, 2H, J=6.4 Hz), 7.58 (s, 1H), 7.36 (d, 2H, J=8.4 Hz), 2.37 (s, 3H), 0.86 (s, 9H), 0.08 (s, 6H); MS (ESI): m/z (%)=285.9 (80%) (M+H)+
Intermediate 2: Preparation of N′-(tert-butyldimethylsilyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00012
A solution of triphenylphosphane (5.05 g, 19.2 mmol, 1.1 eq.) and hexachloro ethane (4.56 g, 19.2 mmol, 1.1 eq.) in chloroform (50 mL) was heated to 70° C. for 5 h. Reaction mixture was cooled to 0° C. and added triethy amine (2.66 g, 26.3 mmol, 1.5 eq.) further a solution of N-(tert-butyldimethylsilyl)-4-methylbenzenesulfonamide (5.0 g, 17.51 mmol, 1.0 eq.) in chloroform (10 mL) was added. After 20 minutes at 0° C., ammonia gas was purged. Reaction mixture was concentrated to yield crude product, which was purified by column chromatography to afford N′-(tert-butyldimethylsilyl)-4-methylbenzenesulfon-imidamide (3.2 g, 64% yield)
1H NMR (DMSO-d6, 400 MHz) δ ppm: 7.54-7.73 (m, 2H), 7.30 (d, 2H, J=8 Hz), 6.57 (s, 2H), 2.35 (s, 3H), 0.87 (s, 9H), 0.00 (s, 6H); MS (ESI): m/z (%)=284.9 (100%) (M+H)+.
Intermediate 3: Preparation of N′-(tert-butyldimethylsilyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00013
To a solution of N′-(tert-butyldimethylsilyl)-4-methylbenzenesulfon-imidamide (1.7 g, 5.98 mmol, 1.0 eq.) in dry THF (25 mL) was added n-BuLi (2.87 mL, 2.5 M, 7.17 mmol, 1.2 eq.) at −78° C. The reaction mixture was stirred at this temperature for 0.5 h and at rt for 0.5 h. 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (1.19 g, 5.98 mmol, 1.0 eq.) was added to the reaction mixture at room temperature (RT) and stirred for 2 h. Reaction mixture was cooled to 0° C. and quenched with NH4Cl. It was diluted with EA (100 mL) and water, layers were separated, aq. layer was back extracted with EA (50 mL×4), all org. layer was combined and washed with water (50 mL), brine (50 mL), dried it over Na2SO4 and conc. under reduced pressure at 45° C. to yield, crude product, which was used for next step.
1H NMR (DMSO-d6, 400 MHz) δ ppm: 9.93 (s, 1H), 8.06 (s, 1H), 7.82 (d, 2H, J=8 Hz), 7.37 (d, 2H, J=8 Hz), 6.90 (s, 1H), 2.78-2.67 (m, 4H), 2.56-2.50 (m, 4H), 2.35 (s, 3H), 1.95-1.91 (m, 4H), 0.90 (s, 9H), 0.00 (s, 6H); MS (ESI): m/z (%)=484.5 (100%) (M+H)+
Intermediate 4: Preparation of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00014
To a solution of N′-(tert-butyldimethylsilyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide (3.3 g, 6.82 mmol, 1.0 eq.) in dry THF (35 mL) was added HCl-dioxane (5.12 mL, 4 M, 7.17 mmol, 3 eq.) at 0° C. The reaction mixture was stirred at this temperature for 0.5 h and at RT for 1 h. Reaction mixture was cooled to 0° C. and quenched with aq. ammonia and waster was added. This mixture was filtered and dried under vacuum to yield N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide as white solid (2.2 g, Yield=87%)
1H NMR (400 MHz, DMSO-d6): δ=9.42 (s, 1H), 7.54 (d, J=7.6 Hz, 2H), 7.34 (d, J=7.6 Hz, 2H), 6.92 (s, 1H), 6.2 (bs, 2H), 2.82-2.79 (m, 8H), 2.36 (s, 3H), 1.82-1.72 (m, 4H); MS (ESI): m/z (%)=370.00 (100%) (M+H)+, 368.05 (100%) (M−H)−
Compound-2 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzene sulfonimidamide
Figure US11236045-20220201-C00015
To a solution of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide (0.1 g, 0.27 mmol, 1.0 eq.) in DMF (1 mL) was added triethylamine (0.15 mL, 1.08 mmol, 4 eq.) and CNBr (0.057 g, 0.54 mmol, 2.0 eq.) at rt. The reaction mixture was stirred at room temperature for 18 h The crude product was purified by preparative HPLC to afford N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzene sulfonimidamide (1.024 g, Yield=22%)
1H NMR (400 MHz, DMSO-d6): δ=7.91 (s, 1H), 7.65 (d, J=8.0 Hz, 2H), 7.27 (d, J=8.0 Hz, 2H), 6.78 (s, 1H), 2.75-2.67 (m, 4H), 2.65-2.56 (m, 4H), 2.34 (s, 3H), 1.92-1.83 (m, 4H); MS (ESI): m/z (%)=395.10 (100%) (M+H)+, 393.15 (100%) (M+H)
Using appropriate starting materials and suitable modifications of the process described in Example 2, including suitable addition and/or deletion of steps as may be necessary, well within the scope of a person skilled in the art, the following compounds were prepared in an analogues manner.
Example-3 N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00016
1H NMR (400 MHz, DMSO-d6): δ=7.74 (s, 1H), 7.64 (d, J=8.0 Hz, 2H), 7.24 (d, J=8.0 Hz, 2H), 7.09 (t, J=8.0 Hz, 1H), 6.99 (d, J=8.0 Hz, 2H), 3.11 (sept, J=7.2 Hz, 2H), 2.33 (s, 3H), 1.08 (d, J=7.2 Hz, 12H); MS (ESI): m/z (%)=399.20 (100%) (M+H)+, 397.15 (100%) (M−H)−.
Example-4 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00017
1H NMR (400 MHz, DMSO-d6): δ=9.42 (s, 1H), 7.54 (d, J=7.6 Hz, 2H), 7.34 (d, J=7.6 Hz, 2H), 6.92 (s, 1H), 6.2 (bs, 2H), 2.82-2.79 (m, 8H), 2.36 (s, 3H), 1.82-1.72 (m, 4H); MS (ESI): m/z (%)=370.00 (100%) (M+H)+, 368.05 (100%) (M−H)−; IR (KBr): v=3379, 3325, 3359, 3207, 2941, 2843, 1651, 1585, 1448, 1375, 1321, 1269 cm−1.
Example-5 N-((2,6-diisopropylphenyl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00018
1H NMR (400 MHz, DMSO-d6): δ=9.69 (bs, 1H), 7.54 (bs, 2H), 7.35 (d, J=8.0 Hz, 2H), 7.19 (s, 1H), 7.08 (d, J=7.6 Hz, 2H), 6.23 (bs, 2H), 3.21 (bs, 2H), 2.36 (s, 3H), 1.06 (d, J=6.8 Hz, 6H), 0.86 (d, J=6.8 Hz, 6H); MS (ESI): m/z (%)=374.10 (100%) (M+H)+, 372.25 (100%) (M−H)−; IR (KBr): v=3338, 3198, 3064, 2966, 2928, 2868, 1705, 1639, 1593, 1462, 1442, 1381, 1265, 1145 cm−1.
Example-6 N-((2,6-diisopropylphenyl)carbamoyl)-4-methyl-N′-(2,2,2-trifluoroethyl)benzenesulfonimi-damide
Figure US11236045-20220201-C00019
1H NMR (400 MHz, DMSO-d6): δ=8.5 (s, 1H), 8.35 (s, 1H), 7.81 (d, J=8.4 Hz, 2H), 7.41 (d, J=8.0 Hz, 2H), 7.19-7.05 (m, 3H), 3.72 (bs, 2H), 3.08 (bs, 2H), 2.38 (s, 3H), 1.1 (d, J=6.4 Hz, 12H); MS (ESI): m/z (%)=456.17 (100%) (M+H)+; (KBr): v=3396, 3142, 2958, 2866, 1616, 1483, 1274, 1242, 1170, 1085, 996 cm−1.
Example-7 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(2,2,2-trifluoroethyl)-benzenesulfonimidamide
Figure US11236045-20220201-C00020
1H NMR (400 MHz, DMSO-d6): δ=8.5 (bs, 1H), 8.47 (s, 1H), 7.77 (bs, 2H),7.42 (d, J=8.0 Hz, 2H), 6.88 (s, 1H), 3.72 (bs, 2H), 2.79 (t, J=6.8 Hz, 4H), 2.68 (bs, 4H), 2.39 (s, 3H), 1.9 (t, J=7.2 Hz, 4H); MS (ESI): m/z (%)=452.20 (100%) (M+H)+.
Example-8 N-((2,6-diisopropylphenyl)carbamoyl)-N′-methoxy-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00021
1H NMR (400 MHz, DMSO-d6): δ=9.82 (bs, 1H), 9.55 (s, 1H), 7.61 (d, J=8.0 Hz, 2H), 7.39 (d, J=8.0 Hz, 2H), 7.24 (t, J=7.6 Hz, 1H), 7.10 (d, J=7.2 Hz, 2H), 3.51 (s, 3H), 3.20 (bs, 2H), 2.43 (s, 3H), 1.06 (s, 6H), 0.74 (s, 6H); MS (ESI): m/z (%)=404.24 (100%) (M+H)+.
Example-9 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-isopropyl-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00022
1H NMR (400 MHz, DMSO-d6): δ=9.35 (s, 1H), 7.54 (bs, 2H),7.35 (d, J=8.0 Hz, 2H), 6.93 (s, 1H), 6.81 (d, J=6.8 Hz, 1H), 3.67 (d, J=6.8 Hz, 1H), 2.80-2.71 (m, 6H), 2.37 (s, 3H), 2.20-2.19 (m, 2H), 1.91-1.82 (m, 4H), 1.06-1.01 (m, 6H); MS (ESI): m/z (%)=412.27 (100%) (M+H)+.
Example-10 N-((2,6-diisopropylphenyl)carbamoyl)-N′-isopropyl-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00023
1H NMR (400 MHz, DMSO-d6): δ=9.56 (s, 1H), 7.55 (d, J=8.0 Hz, 2H), 7.35 (d, J=7.6 Hz, 2H), 7.23 (t, J=6.4 Hz, 1H), 7.09 (d, J=7.6 Hz, 2H), 6.77 (d, J=8.0 Hz, 1H), 3.67 (d, J=7.2 Hz, 1H), 3.22 (bs, 2H), 2.36 (s, 3H), 1.07 (bs, 12H), 0.73 (s, 6H); MS (ESI): m/z (%)=416.30 (100%) (M+H)+.
Example-11 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-methoxy-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00024
1H NMR (400 MHz, DMSO-d6): δ=9.9 (bs, 1H), 9.35 (s, 1H), 7.58 (d, J=8.4 Hz, 2H), 7.38 (d, J=8.4 Hz, 2H), 6.95 (s, 1H), 3.52 (s, 3H), 2.73 (t, J=6.8 Hz, 4H), 2.39 (s, 3H), 2.53-2.22 (m, 4H), 1.85-1.66 (m, 4H); MS (ESI): m/z (%)=400.20 (100%) (M+H)+.
Example 12 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′,4-dimethylbenzenesulfonimidamide
Figure US11236045-20220201-C00025
1H NMR (400 MHz, DMSO-d6): δ=8.4 (bs, 1H), 7.73 (d, J=7.6 Hz, 2H), 7.42-7.36 (m, 3H), 6.87 (s, 1H), 2.79 (t, J=7.2 Hz, 4H), 2.70 (t, J=7.6 Hz, 4H), 2.39 (s, 6H), 1.96 (quin, J=7.6 Hz, 4H); MS (ESI): m/z (%)=384.10 (100%) (M+H)+; IR (KBr): v=3286, 3142, 2939, 2843, 1626, 1521, 1460, 1442, 1427, 1276, 1238, 1120 cm−1.
Example-13 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(1H-pyrazol-5-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00026
1H NMR (400 MHz, DMSO-d6): δ=12.09 (s, 1H), 9.33 (s, 1H), 7.64 (d, J=7.6 Hz, 2H), 7.50 (s, 1H), 7.37 (d, J=8.0 Hz, 2H), 6.96 (s, 1H), 6.30 (s, 1H), 2.76-2.67 (m, 6H), 2.39 (s, 3H), 2.21-2.17 (m, 2H), 1.87-1.84 (m, 4H); MS (ESI): m/z (%)=436.15 (100%) (M+H)+.
Example-14 N′-(4-fluorophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00027
1H NMR (400 MHz, DMSO-d6): δ=10.08 (bs, 1H), 8.35 (s, 1H), 7.71 (s, 2H), 7.36 (d, J=7.2 Hz, 2H), 7.07 (s, 4H), 6.89 (s, 1H), 2.79 (s, 4H), 2.67 (s, 4H), 2.35 (s, 4H), 1.95 (d, J=6.8 Hz, 4H); MS (ESI): m/z (%)=464.35 (100%) (M+H)+.
Example-15 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(pyridin-2-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00028
1H NMR (400 MHz, DMSO-d6): δ=9.38 (bs, 1H), 8.23 (d, J=3.6 Hz, 1H), 7.87 (d, J=6.8 Hz, 1H), 7.70 (d, J=7.6 Hz, 3H), 7.39 (d, J=8.4 Hz, 2H), 7.00 (t, J=7.2 Hz, 2H), 2.80-2.73 (m, 6H), 2.39 (s, 3H), 2.24 (bs, 2H), 1.88-1.70 (m, 4H); MS (ESI): m/z (%)=447.25 (100%) (M+H)+.
Example-16 4-acetyl-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00029
1H NMR (400 MHz, DMSO-d6): δ=8.1 (bs, 1H), 8.06 (d, J=8.4 Hz, 2H), 7.87 (d, J=8.4 Hz, 2H), 6.80 (s, 1H), 2.75-2.70 (m, 4H), 2.67-2.63 (m, 4H), 2.61 (s, 3H), 1.93 (t, J=7.2 Hz, 4H); MS (ESI): m/z (%)=423.10 (100%) (M+H)+; IR (KBr): v=3433, 2949, 2845, 2189, 1687, 1599, 1541, 1263, 1199, 1118, 821 cm−1.
Example-17 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00030
1H NMR (400 MHz, DMSO-d6): δ=8.0 (bs, 1H), 7.67 (d, J=8.4 Hz, 2H), 7.55 (d, J=8.4 Hz, 2H), 6.79 (s, 1H), 5.16 (s, 1H), 2.75 (t, J=7.2 Hz, 4H), 2.68-2.66 (m, 4H), 1.91 (t, J=7.2 Hz, 4H), 1.43 (s, 6H); MS (ESI): m/z (%)=439.15 (100%) (M+H)+.
Example-18 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-nitrobenzenesulfonimidamide
Figure US11236045-20220201-C00031
1H NMR (400 MHz, DMSO-d6): δ=8.48 (s, 1H), 8.37 (d, J=8.4 Hz, 2H), 8.17 (d, J=8.0 Hz, 2H), 7.82 (t, J=8.4 Hz, 2H), 6.80 (s, 1H), 2.78-2.69 (m, 4H), 2.68-2.57 (m, 4H), 1.98-1.81 (m, 4H); MS (ESI): m/z (%)=426.10 (100%) (M+H)+, 448.09 (15%) (M+Na).
Example-19 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methoxybenzenesulfonimidamide
Figure US11236045-20220201-C00032
1H NMR (400 MHz, DMSO-d6): δ=7.93 (s, 1H), 7.70 (d, J=9.2 Hz, 2H), 7.01 (d, J=8.8 Hz, 2H), 6.79 (s, 1H), 3.80 (s, 3H), 2.76 (t, J=7.6 Hz, 4H), 2.70-2.56 (m, 4H), 1.93-1.85 (m, 4H); MS (ESI): m/z (%)=411.19 (100%) (M+H)+, 433.17 (90%) (M+Na).
Example-20 N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methoxybenzenesulfonimidamide
Figure US11236045-20220201-C00033
1H NMR (400 MHz, DMSO-d6): δ=7.55 (d, J=8.8 Hz, 2H), 7.48-7.44 (m, 2H); 7.13 (d, J=9.2 Hz, 2H), 3.83 (s, 3H), 3.06-3.00 (m, 1H), 2.21-2.14 (m, 1H), 1.37 (d, J=6.4 Hz, 3H), 1.17 (d, J=6.8 Hz, 3H), 0.944 (d, J=6.8 Hz, 3H), 0.194 (d, J=6.4 Hz, 3H); MS (ESI): m/z (%)=415.20 (100%) (M+H)+, 437.25 (10%) (M+Na); IR (KBr): v=3464, 2972, 1595, 1525, 1410, 1267, 1147, 1014, 844, 557 cm−1.
Example-21 N′-cyano-4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00034
1H NMR (400 MHz, DMSO-d6): δ=8.03 (br s, 1H), 7.81-7.77 (m, 2H), 7.32 (t, J=8.8 Hz, 2H), 6.79 (s, 1H), 2.73 (t, J=7.2 Hz, 4H), 2.64-2.59 (m, 4H), 1.90-1.87 (m, 4H); MS (ESI): m/z (%)=399.10 (100%) (M+H)+.
Example-22 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00035
1H NMR (400 MHz, DMSO-d6): δ=8.01 (br s, 1H), 7.77-7.75 (m, 2H), 7.49-7.46 (m, 3H), 6.79 (s, 1H), 2.76-2.72 (m, 4H), 2.67-2.60 (m, 4H), 1.93-1.89 (m, 4H).
Example-23 N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)(p-tolyl)-16-sulfanylidene)-methanesulfonamide
Figure US11236045-20220201-C00036
1H NMR (400 MHz, DMSO): δ=11.9 (bs, 1H), 7.8 (bs, 1H), 7.71 (d, J=8 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 6.82 (s, 1H), 2.84 (s, 3H), 2.73-2.84 (m, 4H), 2.59-2.67 (m, 4H), 2.41 (s, 3H), 1.89-1.97 (m, 4H); MS (ESI): m/z (%)=448.35 (30%) (M+H)+; 465.3 (100%) (M+H2O)+.
Example-24 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxypyridine-3-sulfonimidamide
Figure US11236045-20220201-C00037
1H NMR (400 MHz, DMSO-d6): δ=8.51-8.48 (m, 1H), 8.04 (br s, 1H), 8.01-7.93 (m, 1H), 6.92 (d, J=9.2 Hz, 1H), 6.80 (s, 1H), 3.87 (s, 3H), 2.81-2.59 (m, 8H), 1.91-1.84 (m, 4H); MS (ESI): m/z (%)=412.20 (100%) (M+H)+.
Example-25 N′-cyano-3-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00038
1H NMR (400 MHz, DMSO-d6): δ=8.08 (br s, 1H), 7.49-7.47 (m, 1H), 7.43-7.39 (m, 2H), 6.80 (s, 1H), 2.73 (d, J=7.2 Hz, 4H), 2.68-2.58 (m, 4H), 2.28 (s, 3H), 1.93-1.88 (m, 4H); MS (ESI): m/z (%)=413.15 (100%) (M+H)+; IR (KBr): v=3433, 3234, 2951, 2193, 1599, 1577, 1533, 1492 cm−1.
Example-26 4-chloro-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00039
1H NMR (400 MHz, DMSO-d6): δ=8.05 (br s, 1H), 7.74 (d, J=8.8 Hz, 2H), 7.56 (d, J=8.8 Hz, 2H), 6.80 (s, 1H), 2.74 (t, J=7.2 Hz, 4H), 2.68-2.59 (m, 4H), 1.93-1.87 (m, 4H); MS (ESI): m/z (%)=415.10 (100%) (M+H)+; IR (KBr): v=3257, 2945, 2845, 2189, 1678, 1597, 1535 cm−1.
Example-27 4-bromo-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00040
1H NMR (400 MHz, DMSO-d6): δ=8.06 (br s, 1H), 7.71-7.66 (m, 4H), 6.80 (s, 1H), 2.74 (t, J=7.2 Hz, 4H), 2.68-2.59 (m, 4H), 1.93-1.84 (m, 4H); MS (ESI): m/z (%)=459.15 (100%) (M)+; IR (KBr): v=3433, 3236, 2945, 2843, 2191, 1599, 1573, 1531 cm−1.
Example-28 4-(benzyloxy)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00041
1H NMR (400 MHz, DMSO-d6): δ=7.91 (s, 1H), 7.70-7.66 (m, 2H), 7.47-7.45 (m, 2H), 7.42-7.38 (m, 2H), 7.36-7.32 (m, 2H), 7.10-7.05 (m, 3H), 6.79 (s, 1H), 5.16 (s, 1H), 3.34-2.68 (m, 4H), 2.67-2.90 (m, 4H), 1.91-1.89 (m, 4H); MS (ESI): m/z (%)=487.35 (100%) (M+H)+, 509.45 (30%) (M+NH4)+; 485.55 (100%) (M−1); IR (KBr): v=3223, 2947, 2177, 1593, 1496, 1251, 1114, 1095, 827. 698, 532 cm−1.
Example-29 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(trifluoromethyl)-benzenesulfonimidamide
Figure US11236045-20220201-C00042
1H NMR (400 MHz, DMSO-d6, D2O—X): δ=8.12 (br, s, 1H), 7.94 (d, J=8.4 Hz, 2H), 7.88 (d, J=8.4 Hz, 2H), 6.80 (s, 1H), 2.75-2.72 (m, 4H), 2.68-2.55 (m, 4H), 1.91-1.87 (m, 4H); MS (ESI): m/z (%)=449.10 (100%) (M+H)+, 471.15 (30%) (M+Na)+, 447.30 (70%) (M−1)+; IR (KBr): v=3433, 3248, 2195, 1600, 1402, 1323, 1132, 1062, 827, 709 cm−1.
Example-30 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-2-sulfonimidamide
Figure US11236045-20220201-C00043
1H NMR (400 MHz, DMSO): δ=11.9 (bs, 1H), 8.60-8.61 (m, 1H), 8.15 (bs, 1H), 7.86-7.97 (m, 1H), 7.47-7.50 (m, 1H), 7.47-7.49 (m, 1H), 6.79 (s, 1H), 2.75-2.72 (m, 4H), 2.51-2.69 (m, 4H), 1.76-1.91 (m, 4H); MS (ESI): m/z (%)=382.10 (100%) (M+H)+; IR (KBr): v=3431, 2951, 2187, 1616, 1510, 1197 cm−1.
Example-31 Ethyl ((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)(p-tolyl)-λ6-sulfaneylidene)-carbamate
Figure US11236045-20220201-C00044
1H NMR (400 MHz, DMSO): δ=8.10 (bs, 1H), 7.76-7.78 (m, 2H), 7.31 (d, J=7.2 Hz, 2H), 6.85 (s, 1H), 3.85-3.87 (m, 2H), 2.75-2.78 (m, 4H), 2.61-2.67 (m, 4H), 2.36 (s, 3H), 1.92-1.95 (m, 4H), 1.08 (t, J=7.2 Hz, 3H); MS (ESI): m/z (%)=442.30 (100%) (M+H)+; IR (KBr): v=3348, 2953, 2926, 1656, 1460, 1257 cm−1.
Example-32 N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)-(p-tolyl)-λ6-sulfaneylidene)-acetamide
Figure US11236045-20220201-C00045
1H NMR (400 MHz, DMSO): δ=11.9 (bs, 1H), 7.80-8.00 (m, 2H), 7.41 (d, J=8 Hz, 2H), 6.89 (s, 1H), 2.71-2.81 (m, 4H), 2.60-2.69 (m, 4H), 2.39 (s, 3H), 1.91-1.98 (m, 7H); MS (ESI): m/z (%)=412.15 (100%) (M+H)+; IR (KBr): v=3265, 2949, 2845, 1720, 1630, 1247 cm−1.
Example-33 N′-carbamoyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00046
1H NMR (400 MHz, DMSO): δ=8.60 (bs, 1H), 7.75-7.95 (m, 2H), 7.51 (d, j=8.4 Hz, 2H), 6.90 (s, 1H), 2.77-2.80 (m, 4H), 2.65-2.77 (m, 4H), 2.39 (s, 3H), 1.91-2.00 (m, 4H); MS (ESI): m/z (%)=413.15 (100%) (M+H)+.
Example-34 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00047
1H NMR (400 MHz, DMSO-d6): δ=8.0 (bs, 1H), 7.89 (s, 1H), 7.61-7.55 (m, 2H), 7.41-7.37 (m, 1H), 6.79 (s, 1H), 5.19 (s, 1H), 2.76 (t, J=8.0 Hz, 4H), 2.67 (quin, J=7.2 Hz, 4H), 1.90 (t, J=7.6 Hz, 4H), 1.44 (s, 6H); MS (ESI): m/z (%)=439.15 (100%) (M+H)+; IR (KBr): v=3400, 3294, 3257, 2976, 2845, 2196, 1593, 1523, 1288, 1224, 1192 cm−1.
Example-35 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(3-hydroxyoxetan-3-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00048
1H NMR (400 MHz, DMSO-d6): δ=8.0 (bs, 1H), 7.79 (d, J=8.8 Hz, 2H), 7.70 (d, J=8.4 Hz, 2H), 6.79 (s, 1H), 6.49 (s, 1H), 4.79 (d, J=6.8 Hz, 2H), 4.71 (d, J=6.0 Hz, 2H), 2.76 (t, J=7.2 Hz, 4H), 2.67 (quin, J=7.2 Hz, 4H), 1.91 (t, J=7.6 Hz, 4H); MS (ESI): m/z (%)=453.25 (100%) (M+H)+.
Example-36 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(prop-1-en-2-yl)furan-2-sulfonimidamide
Figure US11236045-20220201-C00049
1H NMR (400 MHz, DMSO-d6): δ=9.4 (s, 1H), 8.1 (bs, 1H), 7.87 (s, 1H), 7.03 (s, 1H), 6.82 (s, 1H), 5.34 (s, 1H), 4.97 (s, 1H), 2.82-2.73 (m, 4H), 2.68-2.65 (m, 4H), 1.95 (s, 3H), 1.91 (t, J=7.6 Hz, 4H); MS (ESI): m/z (%)=411.13 (100%) (M+H)+, 409.08 (100%) (M−H); IR (KBr): v=3433, 3255, 2946, 2845, 21963, 1656, 1600, 1531, 1460, 1274 cm−1.
Example-37 5-bromo-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiophene-2-sulfonimidamide
Figure US11236045-20220201-C00050
1H NMR (400 MHz, DMSO-d6): δ=8.13 (bs, 1H), 7.24 (s, 1H), 7.20 (s, 1H), 6.63 (s, 1H), 2.76 (bs, 4H), 2.68 (q, J=6.4 Hz, 4H), 1.93 (t, J=6.4 Hz, 4H); MS (ESI): m/z (%)=466.10 (100%) (M+H)+, 465.30 (100%) (M−H); IR (KBr): v=3433, 3244, 2955, 2922, 2202, 2183, 1595, 1533, 1460, 1402, 1276 cm−1.
Example-38 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methoxybenzenesulfonimidamide
Figure US11236045-20220201-C00051
1H NMR (400 MHz, DMSO-d6): δ=8.26 (bs, 1H), 7.42 (t, J=7.6 Hz, 1H), 7.35 (t, J=8.0 Hz, 1H), 7.28 (t, J=2.0 Hz, 1H), 7.07-7.05 (m, 1H), 6.80 (s, 1H), 3.79 (s, 3H), 2.76 (t, J=7.6 Hz, 4H), 2.68-2.63 (m, 4H), 1.93 (qui, J=6.8 Hz, 4H); MS (ESI): m/z (%)=411.20 (100%) (M+H)+, 409.20 (100%) (M−H); IR (KBr): v=3423, 3225, 2937, 2848, 2198, 2175, 1597, 1541, 1483, 1460, 1427 cm−1.
Example-39 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonimidamide
Figure US11236045-20220201-C00052
1H NMR (400 MHz, DMSO-d6): δ=8.10 (bs, 1H), 7.55 (s, 1H), 6.82 (s, 1H), 6.79 (s, 1H), 5.03 (s, 1H), 2.77 (t, J=7.2 Hz, 4H), 2.68 (t, J=7.2 Hz, 4H), 1.94 (qui, J=7.2 Hz, 4H), 1.38 (s, 6H); MS (ESI): m/z (%)=429.20 (100%) (M+H)+, 427.30 (100%) (M−H); IR (KBr): v=3389, 3138, 2949, 2843, 2191, 1620, 1512, 1274, 1240, 1197, 1118 cm−1.
Example-40 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonimidamide
Figure US11236045-20220201-C00053
1H NMR (400 MHz, DMSO-d6): δ=7.96 (bs, 1H), 7.23 (d, J=6.8 Hz, 2H), 6.94 (d, J=9.2 Hz, 1H), 6.80 (s, 1H), 4.28 (s, 4H), 2.76 (t, J=7.2 Hz, 4H), 2.69-2.61 (m, 4H), 1.94 (qui, J=7.2 Hz, 4H); MS (ESI): m/z (%)=439.10 (100%) (M+H)+, 437.10 (100%) (M−H); IR (KBr): v=3431, 3232, 2928, 2195, 2179, 1595, 1537, 1496, 1458, 1421, 1128, 1151 cm−1.
Example-41 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)thiophene-2-sulfonimidamide
Figure US11236045-20220201-C00054
1H NMR (400 MHz, DMSO-d6): δ=7.95 (bs, 1H), 7.23 (d, J=4.0 Hz, 1H), 6.82 (d, J=4.0 Hz, 1H), 6.81 (s, 1H), 5.63 (s, 2H), 2.77 (t, J=7.2 Hz, 4H), 2.68-2.65 (m, 4H), 1.94 (qui, J=7.2 Hz, 4H), 1.49 (s, 6H); MS (ESI): m/z (%)=445.10 (100%) (M+H)+, 443.10 (100%) (M−H).
Example-42 N′-cyano-2-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methylbenzene-sulfonimidamide
Figure US11236045-20220201-C00055
1H NMR (400 MHz, DMSO-d6): δ=8.06 (bs, 1H), 7.55 (d, J=5.2 Hz, 1H), 7.32-7.30 (m, 1H), 7.16-7.12 (m, 1H), 6.80 (s, 1H), 2.76 (t, J=7.2 Hz, 4H), 2.68-2.64 (m, 4H), 2.31 (s, 3H), 1.94 (qui, J=7.6 Hz, 4H); MS (ESI): m/z (%)=413.13 (100%) (M+H)+; IR (KBr): v=3433, 3246, 2929, 2845, 2196, 2179, 1595, 1573, 1531, 1492, 1460, 1251 cm−1.
Example-43 N′-cyano-3-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00056
1H NMR (400 MHz, DMSO-d6): δ=8.95 (s, 1H), 8.14 (S, 1H), 8.04 (s, 1H), 7.92 (d, J=8.0 Hz, 1H), 7.78 (d, J=8.0 Hz, 1H), 7.66 (t, J=7.6 Hz, 1H), 6.79 (s, 1H), 2.75 (t, J=6.8 Hz, 4H), 2.62 (t, J=6.8 Hz, 4H), 1.91 (quin, J=6.8 Hz, 4H); MS (ESI): m/z (%)=547.05 (100%) (M+H)+, 545.10 (100%) (M−H); IR (KBr): v=3369, 2955, 2847, 2189, 1610, 1510, 1269, 1197 cm−1.
Example-44 N′-cyano-3,5-difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00057
1H NMR (400 MHz, DMSO-d6): δ=8.20 (s, 1H), 7.49-7.44 (m, 1H), 7.39-7.34 (m, 2H), 6.82 (S, 1H), 2.72 (t, J=7.2 Hz, 4H), 2.62 (quin, J=7.6 Hz, 4H), 1.94 (t, J=7.2 Hz, 4H); MS (ESI): m/z (%)=417.05 (100%) (M+H)+, 415.05 (100%) (M−H); IR (KBr): v=3238, 3086, 2956, 2196, 2181, 1597, 1537, 1444, 1278 cm−1.
Example 45 N′-cyano-2,4-difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00058
1H NMR (400 MHz, DMSO-d6): δ=8.05 (bs, 1H), 7.84-7.78 (m, 1H), 7.38-7.32 (m, 1H), 7.20-7.15 (m, 1H), 6.80 (S, 1H), 2.76 (t, J=7.2 Hz, 4H), 2.69-2.61 (m, 4H), 1.93 (quin, J=7.2 Hz, 4H); MS (ESI): m/z (%)=416.99 (100%) (M+H)+; IR (KBr): v=3433, 3255, 2947, 2845, 2195, 1602, 1525, 1487, 1201 cm−1.
Example-46 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(trifluoromethoxy)-benzenesulfonimidamide
Figure US11236045-20220201-C00059
1H NMR (400 MHz, DMSO-d6): δ=8.15 (bs, 1H), 7.78 (d, J=8.0 Hz, 1H), 7.67-7.63 (m, 2H), 7.53 (d, J=8.0 Hz, 1H), 6.80 (S, 1H), 2.76 (t, J=7.2 Hz, 4H), 2.64 (t, J=8.0 Hz, 4H), 1.91 (t, J=4.8 Hz, 4H); MS (ESI): m/z (%)=464.91 (100%) (M)+; IR (KBr): v=3433, 2953, 2847, 2185, 1608, 1261, 1207 cm−1.
Example-47 N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00060
1H NMR (400 MHz, DMSO-d6): δ=7.89 (s, 1H), 7.78 (S, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.56 (d, J=7.6 Hz, 1H), 7.38 (t, J=8.0 Hz, 1H), 7.12 (t, J=7.6 Hz, 1H), 7.01 (d, J=7.6 Hz, 2H), 5.17 (s, 1H), 3.12 (bs, 2H), 1.43 (6, 1H), 1.08 (d, J=6.8 Hz, 12H); MS (ESI): m/z (%)=442.97 (100%) (M+H)+; IR (KBr): v=3385, 2964, 2868, 2181, 1608, 1475, 1384, 1207, 1128, 844 cm−1.
Example-48 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-phenylmethanesulfonimidamide
Figure US11236045-20220201-C00061
1H NMR (400 MHz, DMSO-d6): δ=7.87 (bs, 1H), 7.43-7.30 (m, 5H), 6.84 (S, 1H), 4.66 (d, J=13.2 Hz, 1H), 4.57 (d, J=13.2 Hz, 1H), 2.81-2.72 (m, 8H), 1.99 (quin, J=7.6 Hz, 4H); MS (ESI): m/z (%)=395.15 (100%) (M+H)+, 417.14 (20%) (M+Na)+; IR (KBr): v=3315, 2945, 2845, 2119, 1604, 1525, 1290, 1234, 1203, 945, 694 cm−1.
Example-49 N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(3-(2-hydroxypropan-2-yl)phenyl)(oxo)-16-sulfaneylidene)methanesulfonamide
Figure US11236045-20220201-C00062
1H NMR (400 MHz, DMSO-d6): δ=10.67 (s, 1H), 7.92 (s, 1H), 7.73 (m, 2H), 7.59 (d, J=15.6 Hz, 1H), 7.47-7.43 (m, 4H), 7.26-7.22 (m, 1H), 7.11 (d, J=8.0 Hz, 2H), 3.04-2.97 (m, 2H), 1.04 (s, 12H); MS (ESI): m/z (%)=491.89 (50%) (M+H)+, 513.86 (100%) (M+Na), 489.95 (100%) (M−1).
Example-50 N′-cyano-N-((1,2,3,6,7,8-hexahydro-as-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide
Figure US11236045-20220201-C00063
1H NMR (400 MHz, DMSO-d6): δ=7.65 (d, J=8.4 Hz, 2H), 7.63 (s, 1H), 7.33 (s, 1H), 7.28 (d, J=8.4 Hz, 2H), 3.09 (m, 4H), 2.67 (m, 4H), 2.35 (s, 3H), 1.97 (m, 4H); MS (ESI): m/z (%)=395.2 (100%) (M+1); IR (KBr): v=3362, 2960, 2847, 2206, 1593, 1519, 1421, 1280, 1182 cm−1.
Example 51 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiophene-2-sulfonimidamide
Figure US11236045-20220201-C00064
1H NMR (400 MHz, DMSO-d6): δ=8.01 (s, 1H), 7.72 (d, J=1.2 Hz, 1H), 7.43 (d, J=2.0 Hz, 1H), 7.06 (d, J=4.8 Hz, 1H), 6.81 (s. 1H), 2.73 (m, 4H), 2.64 (m, 4H), 1.90 (m, 4H); MS (ESI): m/z (%)=387 (M+1).
Example 52 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,4-dimethoxybenzene-sulfonimidamide
Figure US11236045-20220201-C00065
1H NMR (400 MHz, DMSO-d6): δ=7.95 (s, 1H), 7.34 (d, J=2.0 Hz, 1H), 7.29 (d, J=2.0 Hz, 1H), 7.04 (d, J=8.8 Hz, 1H), 6.69 (s, 1H), 3.94 (s, 3H). 3.80 (s, 3H), 2.73 (m, 4H), 2.64 (m, 4H), 2.09 (m, 4H); MS (ESI): m/z (%)=441.2 (100%) (M+1); IR (KBr): v=−3423.76, 2939.6, 2191.21, 1595.18, 1508.38, 1261.49, 941.29 cm−1.
Example 53 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methylpyridine-2-sulfonimidamide
Figure US11236045-20220201-C00066
1H NMR (400 MHz, DMSO): δ=8.10 (bs, 1H), 7.85-7.81 (m, 1H), 7.68-7.66 (m, 1H), 7.34-7.36 (m, 1H), 6.79 (s, 1H), 2.75-2.70 (m, 4H), 2.68-2.55 (m, 4H), 2.50 (s, 3H), 1.99-1.86 (m, 4H); MS (ESI): m/z (%)=396.30 (100%) (M+H)+; IR (KBr): v=3367, 2949, 2189, 1732, 1612, 1195 cm−1.
Example 54 N′,3-dicyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00067
1H NMR (400 MHz, DMSO): δ=8.20 (bs, 1H), 8.06-7.98 (m, 3H), 7.76-7.72 (m, 1H), 6.81 (s, 1H), 2.76-2.50 (m, 8H), 1.93-1.88 (m, 4H); MS (ESI): m/z (%)=405.95 (100%) (M+H)+; IR (KBr): v=3412, 2949, 2191, 1599, 1251, 1205 cm−1.
Example 55 N′,4-dicyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00068
1H NMR (400 MHz, DMSO): δ=8.15 (bs, 1H), 8.00-7.97 (m, 2H), 7.89-7.88 (m, 2H), 6.80 (s, 1H), 2.80-2.50 (m, 8H), 1.93-1.19 (m, 4H); MS (ESI): m/z (%)=406.10 (100%) (M+H)+; IR (KBr): v=3433, 3246, 2196, 1597, 1246 cm−1.
Example 56 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-3-sulfonimidamide
Figure US11236045-20220201-C00069
1H NMR (400 MHz, DMSO): δ=8.87 (d, J=2 Hz, 1H), 8.67-7.66 (m, 1H), 8.10 (bs, 1H), 8.09-8.07 (m, 1H), 7.56-7.53 (m, 1H), 6.80 (s, 1H), 2.76-2.60 (m, 8H), 1.91-1.87 (m, 4H); MS (ESI): m/z (%)=382.05 (100%) (M+H)+; IR (KBr): v=3267, 2951, 2193, 1599, 1257, 1232 cm−1.
Example 57 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-4-sulfonimidamide
Figure US11236045-20220201-C00070
1H NMR (400 MHz, DMSO): δ=8.74-8.73 (m, 2H), 8.20 (bs, 1H), 7.66-7.64 (m, 2H), 6.81 (s, 1H), 2.76-2.59 (m, 8H), 1.91-1.87 (m, 4H); MS (ESI): m/z (%)=382.13 (100%) (M+H)+; IR (KBr): v=3236, 2951, 2181, 1739, 1599, 1247 cm−1.
Example 58 N′-cyano-3-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
Figure US11236045-20220201-C00071
1H NMR (400 MHz, DMSO-d6): δ=8.11 (s, 1H), 7.58 (d, J=6.4 Hz, 2H), 7.48 (d, J=8.8 Hz, 1H), 7.37 (d, J=2.8 Hz, 1H), 6.80 (s, 1H), 2.82 (m, 4H), 2.64 (m, 4H), 1.91 (m, 4H); MS (ESI): m/z (%)=397 (100%) (M−1).
Example 59 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)quinoline-8-sulfonimidamide
Figure US11236045-20220201-C00072
1H NMR (400 MHz, DMSO-d6): δ=9.02 (s, 1H), 8.64 (d, J=9.2 Hz, 1H), 8.46 (d, J=8.0 Hz, 1H), 8.20 (d, J=7.2 Hz, 1H), 7.78 (m, 1H), 7.72 (d, J=7.6 Hz, 1H), 7.12 (s, 1H), 3.23 (m, 1H), 2.91 (m, 4H), 2.75 (m, 4H), 2.01 (m, 4H); MS (ESI): m/z (%)=432.13 (100%) (M+1).
Example 60 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-morpholinobenzene sulfonimidamide
Figure US11236045-20220201-C00073
1H NMR (400 MHz, DMSO-d6): δ=7.87 (s, 1H), 7.59 (d, J=9.2 Hz, 2H), 6.97 (d, J=8.8 Hz, 2H), 6.79 (s, 1H), 3.73 (t, J=4.8 Hz, 4H), 3.20 (t, J=4.8 Hz, 4H), 2.85 (m, 4H), 2.65 (m, 4H), 1.91 (m, 4H); MS (ESI): m/z (%)=466.12 (100%) (M+1); IR (KBr): v=3442, 2949, 2177, 1593, 1504, 1379, 1240, 1190, 927 cm−1.
Example 61 N-(3-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)phenyl) acetamide
Figure US11236045-20220201-C00074
1H NMR (400 MHz, DMSO-d6): δ=10.16 (s, 1H), 7.96 (s, 2H), 7.76 (s, 1H), 7.39 (d, J=2.0 Hz, 2H), 6.79 (s, 1H), 2.85 (m, 4H), 2.55 (m, 4H), 2.05 (s, 3H), 1.85 (m, 4H); MS (ESI): m/z (%)=435.9 (100%) (M−1); IR (KBr): v=3433, 2918, 2173, 1701, 1599, 1545, 1384, 1215, 1163, 1126, 840 cm−1.
Example 62 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-morpholinobenzene sulfonimidamide
Figure US11236045-20220201-C00075
1H NMR (400 MHz, DMSO-d6): δ=8.0 (s, 1H), 7.31 (d, J=8.0 Hz, 2H), 7.20 (d, J=8.0 Hz, 2H), 7.07 (d, J=1.60 Hz, 1H), 6.80 (s, 1H), 3.75 (t, J=4.8 Hz, 4H), 3.12 (t, J=4.8 Hz, 4H), 2.74 (m, 4H), 2.71 (m, 4H), 1.95 (m, 4H); MS (ESI): m/z (%)=465.98 (100%) (M+1); IR (KBr): v=3433, 3225, 2955, 2195, 1595, 1539, 1485, 1379, 1280, 1120, 937 cm−1.
Example 63 N′-cyano-4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00076
1H NMR (400 MHz, DMSO): δ=8.13 (dd, J=2.4 Hz, J=7.6 Hz, 1H), 8.00 (bs, 1H), 7.68-7.64 (m, 1H), 7.24-7.19 (m, 2H), 6.79 (s, 1H), 2.76-2.60 (m, 8H), 1.95-1.85 (m, 4H), 1.50 (s, 3H), 1.48 (s, 3H); MS (ESI): m/z (%)=456.88 (100%) (M+H)+; IR (KBr): v=3369, 2953, 2185, 1614, 1215 cm−1.
Example 64 N′-cyano-2-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)benzenesulfonimidamide
Figure US11236045-20220201-C00077
1H NMR (400 MHz, DMSO): δ=8.10 (bs, 1H), 7.88 (dd, J=2.4 Hz, J=7.2 Hz, 1H), 7.56-7.55 (m, 1H), 7.19-7.15 (m, 1H), 6.80 (s, 1H), 5.22 (s, 1H), 2.76-2.61 (m, 8H), 1.99-1.87 (m, 4H), 1.42 (s, 6H); MS (ESI): m/z (%)=456.90 (100%) (M+H)+; IR (KBr): v=3412, 2949, 2196, 1595, 1195 cm−1.
Example 65 N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)pyridine-3-sulfonimidamide
Figure US11236045-20220201-C00078
1H NMR (400 MHz, DMSO): δ=8.75-8.72 (m, 2H), 8.22-8.14 (m, 2H), 6.80 (s, 1H), 5.43 (s, 1H), 2.90-2.60 (m, 8H), 1.99-1.76 (m, 4H), 1.48 (s, 3H), 1.47 (s, 3H); MS (ESI): m/z (%)=439.83 (100%) (M+H)+.
Example 66 N′-cyano-1-(4-cyanophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-methanesulfonimidamide
Figure US11236045-20220201-C00079
1H NMR (400 MHz, DMSO-d6): δ=7.94 (bs, 1H), 7.82 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.0 Hz, 2H), 6.84 (S, 1H), 4.78 (d, J=13.2 Hz, 1H), 4.68 (d, J=12.8 Hz, 1H), 2.79 (t, J=7.2 Hz, 4H), 2.73 (t, J=7.2 Hz, 4H), 1.97 (quin, J=7.2 Hz, 4H); MS (ESI): m/z (%)=420.17 (100%) (M+H)+, 442.15 (20%) (M+Na)+; IR (KBr): v=3290, 2951, 2850, 2229, 2189, 1720, 1602, 1529, 1460, 1286, 1228, 1161 cm−1.
Example 67 1-(4-cyanophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonimidamide
Figure US11236045-20220201-C00080
1H NMR (400 MHz, DMSO-d6): δ=8.2 (bs, 1H), 7.78 (d, J=8.0 Hz, 2H), 7.58 (d, J=7.6 Hz, 2H), 7.06 (S, 2H), 6.89 (S, 1H), 4.89 (d, J=13.2 Hz, 1H), 4.75 (d, J=13.2 Hz, 1H), 2.80 (t, J=7.2 Hz, 4H), 2.67 (t, J=7.2 Hz, 4H), 1.96 (t, J=7.2 Hz, 4H); MS (ESI): m/z (%)=395.15 (50%) (M+H)+, 393.04 (100%) (M−H)+; IR (KBr): v=3275, 3176, 2949, 2843, 2231, 1618, 1531, 1460, 1288, 1246, 1151, 829 cm−1.
Example 68 N′-cyano-3-(2-hydroxypropan-2-yl)-N-((3-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carba-moyl)-benzenesulfonimidamide
Figure US11236045-20220201-C00081
1H NMR (400 MHz, DMSO-d6): δ=8.89 (s, 1H), 7.92 (S, 1H), 7.60 (q, J=7.6 Hz, 2H), 7.41 (t, J=7.6 Hz, 1H), 7.00 (s, 1H), 5.21 (s, 1H), 2.82 (t, J=4.4 Hz, 2H), 2.82 (t, J=7.6 Hz, 2H), 2.77-2.67 (m, 4H), 1.85 (t, J=6.0 Hz, 2H), 1.43 (s, 6H); MS (ESI): m/z (%)=453.35 (100%) (M+H)+, 475.35 (50%) (M+Na)+; IR (KBr): v=3421, 2964, 2926, 2181, 1672, 1651, 1614, 1508, 1460, 1419, 1251, 1190 cm−1.
Biological Activity:
In-Vitro Assays:
THP1 (Tamm-Horsfall Protein 1) monocytes were differentiated with PMA (Phorbol 12-myristate 13-acetate) (100 ng/ml) and incubated at 37° C. for 20 h in presence of 5% CO2. 2×105 differentiated cells were plated per well of 96 well tissue culture plates. The cells were primed using 500 ng/ml Lipopolysaccharide and incubating for 4 hrs under the same condition. The cells were then treated with various concentrations of the compounds for 30 min followed by treatment with 5 mM ATP for 1 hr. The supernatants were collected and analysed by IL-1b (Mabtech Cat #3415-1H-20) or TNF-a (Mabtech; Cat #3510-1H-20) detection kit. The data were analyzed using GraphPad Prism V7.0. Dose Response Curve (DRC) was constructed to determine the IC50 value by fitting percentage cell survival data to the GraphPad Prism using nonlinear regression analysis. The in vitro IL-1β inhibitory activity (IC50) for representative compounds is listed in Table 1:
TABLE 1
Compound IC50 (nM)
Example 1 6.6
Example 17 12
Example 18 15
Example 19 23
Example 21 62
Example 22 13
Example 24 34
Example 25 5
Example 26 23
Example 27 27
Example 29 32
Example 30 28
Example 34 3
Example 35 13
Example 36 32
Example 37 5.6
Example 38 17
Example 39 3.3
Example 40 13
Example 41 4.8
Example 42 2.4
Example 43 27
Example 44 63
Example 45 23
Example 46 —
Example 48 3.5
Example 51 19
Example 52 4.4
Example 53 45
Example 54 12
Example 55 27
Example 56 43
Example 58 38
Example 63 7.8
Example 64 7.7
Example 65 1.26
Example 66 4

In Vivo Efficacy Studies:
Demonstration of in vivo efficacy of test compounds in rats mice, oral routes of administration.
Animals
All the animal experiments were carried out in female rats and mice, bred in-house. Animals were housed in groups of 6 animals per cage, for a week, in order to habituate them to vivarium conditions (25±4° C., 60-65% relative humidity, 12:12 h light:dark cycle, with lights on at 7.30 am). All the animal experiments were carried out according to the internationally valid guidelines following approval by the ‘Zydus Research Center animal ethical committee’.
In-Vivo LPS and ATP Induced IL-1β Assay:
Female C57 mice (6-8 weeks) received intraperitoneal injection of 50 μg/mouse of lipopolysaccharide (LPS) in PBS. Animals were treated immediately with the test compounds or the vehicle. After 2 h of LPS injection, animals were administered with ATP at 12.5 mg/mouse dissolved in PBS via intraperitoneal route. After 30 minutes of ATP injection, serum was collected for IL-1β estimation by ELISA.
The novel compounds of the present invention can be formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.
The compounds of formula (I) or pharmaceutical compositions containing them are useful as a medicament for the inhibition of NLRP3 activity and suitable for humans and other warm blooded animals, and may be administered either by oral, topical or parenteral administration. Thus, a pharmaceutical composition comprising the compounds of the present invention may comprise a suitable binder, suitable bulking agent &/or diluent and any other suitable agents as may be necessary. Optionally, the pharmaceutical composition may be suitably coated with suitable coating agents.
The compounds of the present invention (I) are NLRP3 inhibitors and are useful in the treatment of disease states mediated by NLRP3, preferably diseases or conditions in which interleukin 1 β activity in which interleukin 1β activity and interleukin-18 (IL-18) are implicated and related disorders.
The quantity of active component, that is, the compounds of Formula (I) according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.
The compounds of the present invention, formula (I), may be used alone or in any combination with one or more other therapeutic agents which a skilled medical practitioner can easily identify. Such other therapeutic agent may be selected depending on the type of disease being treated, the severity, other medications being taken by the patients etc. Thus for example, for treatment of rheumatoid arthritis, one or more DMARDs may be used in combination with the compounds of the present invention.
In one of the embodiments compound of formula (I) of the present invention may be used in combination with one or more suitable pharmaceutically active agents selected from following therapeutic agents in any combination. Inhibitors of interleukin-1β (e.g. rilonacept, canakinumab, and anakinra); immune-suppressants (e.g., Methotrexate, mercaptopurine, cyclophosphamide), metabolic disorders drugs, glucocorticoids, non-steroidal anti-inflammatory drugs, Cox-2 specific inhibitors, TNF-α binding proteins (eg., Infliximab, etanercept), interferon-13, interferon, interleukin-2, antihistamines, beta-agonist, BTK inhibitors, anticholinergics, anti-cancer agents or their suitable pharmaceutically acceptable salts. Further examples for use in combination with Non-Alcoholic Steato-Hepatitis (NASH) and fibrosis drugs, anticancer antibiotics, hormones, Aromatase inhibitors, antibodies, cytokines, vaccines, drug conjugates, inhibitors of mitogen-activated protein kinase signaling (ex: BAY 43-9006), Syk inhibitors, mTOR inhibitors, antibodies (Rituxan), and BCR/ABL antagonist.

Claims (7)

What is claimed is:
1. A compound having the structure of general formula (I)
Figure US11236045-20220201-C00082
wherein
‘A’ is selected from unsubstituted or substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C3-C6)cycloalkyl, aryl, heteroaryl and heterocyclyl groups having optionally one or more than one heteroatom;
‘B’ is the following ring system
Figure US11236045-20220201-C00083
wherein X, Y, Z at each occurrence is independently selected from C, N, S, SO2, and O, which may be optionally substituted;
n=0-3;
R1 at each occurrence independently represents hydrogen, halogen, haloalkyl, cyano, optionally substituted groups selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, (C3-C6)cycloalkyl, aryl, heteroaryl, heterocyclyl, benzyl, mercapto alkyl, sulfur and its oxidized forms;
when A represents a ring, R1 may additionally represent thiol, sulfur and its oxidized forms, C1-C6(thio-alkoxy), bridged or spiro ring system having optionally one or more than one heteroatom;
R2 at each occurrence independently represents hydrogen, halide, cyano, optionally substituted groups selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy (C3-C6)cycloalkyl, benzyl, aryl, heteroaryl, heterocyclyl, thiol, thioalkyl, thio-alkoxy sulfur and its oxidized forms, bridged or spiro ring system having optionally one or more than one heteroatom;
R3 at each occurrence independently represents hydrogen, hydroxyl, halogen, nitro, cyano, optionally substituted groups selected from (C1-C10)alkyl, (C1-C10)alkoxy, (C3-C10)cycloalkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, SO2(C1-C6)alkyl, benzyl, aryl, heteroaryl, heterocyclyl, thiol, thioalkyl, thio-alkoxy, sulfur and its oxidized forms, or R3 and A together with the atom to which they are attached may form an optionally substituted 5 to 7 membered heterocyclic ring system having optionally one or more than one heteroatom; ‘m’ represents an integer from 1-5;
R4 at each occurrence is independently selected from hydrogen, halogen, cyano, amide, sulphonamide, acyl, hydroxyl, optionally substituted groups selected from (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C6)cycloalkyl, and (C1-C6)alkoxy;
wherein the substitutions on any of the optionally substituted groups above are independently selected from hydrogen, hydroxy, cyano, halo, haloalkyl, haloalkyloxy, alkylthio (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, C1-C6alkoxy, —COR10, —CSR10, C(O)OR10, C(O)—R10, —C(O)—NR11R12, —C(S)—NR11R12, —SO2R10 group, wherein R10 is independently selected from hydrogen, optionally substituted group selected from (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C7)cycloalkyl, aryl, heteroaryl, and heterocyclyl group; each of R11 and R12 are independently selected from hydrogen, optionally substituted group selected from (C1-C6)alkyl, (C1-C6)alkoxy, aryl and benzyl group.
2. The compound as claimed in claim 1, wherein R4 at each occurrence is independently selected from hydrogen, halogen, (C1-C6)alkyl, and (C1-C6)alkoxy groups.
3. A compound as claimed in claim 1 selected from the group consisting of:
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzene sulfonimidamide;
N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methylbenzenesulfonimidamide;
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
N-((2,6-diisopropylphenyl)carbamoyl)-4-methylbenzenesulfonimidamide;
N-((2,6-diisopropylphenyl)carbamoyl)-4-methyl-N′-(2,2,2-trifluoroethyl)benzenesulfonimidamide;
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(2,2,2-trifluoroethyl)-benzenesulfonimidamide;
N-((2,6-diisopropylphenyl)carbamoyl)-N′-methoxy-4-methylbenzenesulfonimidamide;
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-isopropyl-4-methylbenzenesulfonimidamide;
N-((2,6-diisopropylphenyl)carbamoyl)-N′-isopropyl-4-methylbenzenesulfonimidamide;
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′-methoxy-4-methylbenzenesulfo-nimidamide;
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-N′,4-dimethylbenzenesulfonimidamide;
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(1H-pyrazol-5-yl)benzenesulfonimidamide;
N′-(4-fluorophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methyl-N′-(pyridin-2-yl)benzenesulfonimidamide;
4-acetyl-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-nitrobenzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methoxybenzenesulfonimidamide;
N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-4-methoxybenzenesulfonimidamide;
N′-cyano-4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)(p-tolyl)-16-sulfanylidene)-methanesulfonamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methoxypyridine-3-sulfonimidamide;
N′-cyano-3-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
4-chloro-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
4-bromo-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
4-(benzyloxy)-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzene-sulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(trifluoromethyl)-benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-2-sulfonimidamide;
ethyl ((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)(p-tolyl)-λ6-sulfanylidene)-carbamate;
N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(oxo)-(p-tolyl)-λ6-sulfanylidene)-acetamide;
N′-carbamoyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(3-hydroxyoxetan-3-yl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(prop-1-en-2-yl)furan-2-sulfonimidamide;
5-bromo-N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiophene-2-sulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-methoxybenzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonimidamide
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2,3-dihydrobenzo[b][1,4] dioxine-6-sulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)thiophene-2-sulfonimidamide;
N′-cyano-2-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-methylbenzenesulfonimidamide;
N′-cyano-3-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide
N′-cyano-3,5-difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
N′-cyano-2,4-difluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(trifluoromethoxy)-benzenesulfonimidamide;
N′-cyano-N-((2,6-diisopropylphenyl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-phenylmethanesulfonimidamide;
N-((3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)ureido)(3-(2-hydroxypropan-2-yl)phenyl)(oxo)-16-sulfaneylidene)methanesulfonamide;
N′-cyano-N-((1,2,3,6,7,8-hexahydro-as-indacen-4-yl)carbamoyl)-4-methylbenzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)thiophene-2-sulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3,4-dimethoxybenzene-sulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-methylpyridine-2-sulfonimidamide;
N′,3-dicyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
N′,4-dicyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)pyridine-4-sulfonimidamide;
N′-cyano-3-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzene sulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)quinoline-8-sulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-morpholinobenzene sulfonimidamide;
N-(3-(N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamidimidoyl)phenyl) acetamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-morpholinobenzene sulfonimidamide;
N′-cyano-4-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-3-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
N′-cyano-2-fluoro-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)benzenesulfonimidamide;
N′-cyano-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxypropan-2-yl)pyridine-3-sulfonimidamide;
N′-cyano-1-(4-cyanophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-methanesulfonimidamide;
1-(4-cyanophenyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonimidamide; and
N′-cyano-3-(2-hydroxypropan-2-yl)-N-((3-oxo-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carba-moyl)-benzenesulfonimidamide.
4. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1 and optionally one or more pharmaceutically acceptable carriers, diluents or excipients.
5. The pharmaceutical composition as claimed in claim 4 in combination with one or more suitable pharmaceutically active agents selected from inhibitors of interleukin-1β; immune-suppressants; metabolic disorders drugs, glucocorticoids, non-steroidal anti-inflammatory drugs, COX-2 specific inhibitors, TNF-α binding proteins, interferon-13, interferon, interleukin-2, antihistamines, beta-agonists, BTK inhibitors, anticholinergics, anti-cancer agents or their suitable pharmaceutically acceptable salts, Non-Alcoholic Steato-Hepatitis (NASH) and fibrosis drugs, antibiotics, hormones, aromatase inhibitors, inhibitors of mitogen-activated protein kinase signaling, Syk inhibitors, mTOR inhibitors, and BCR/ABL antagonists.
6. A method of administering the composition of claim 4 for treating diseases or conditions in which interleukin 1 activity and interleukin-18 (IL-18) are implicated selected from lymphoma, inflammatory bowel diseases (IBD), auto-immune diseases, heteroimmune diseases, inflammatory diseases, cancer, and neurodegenerative diseases.
7. A method of administering the composition of claim 4 for treating diseases or conditions in which interleukin 1 activity and interleukin-18 (IL-18) are implicated selected from inflammation, Cryopyrin-associated periodic syndromes (CAPS), gouty arthritis, type 2 diabetes, atherosclerosis, and liver fibrosis.
US16/617,389 2017-06-09 2018-06-08 Substituted sulfoximine compounds Expired - Fee Related US11236045B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201721020305 2017-06-09
IN201721020305 2017-06-09
PCT/IB2018/054134 WO2018225018A1 (en) 2017-06-09 2018-06-08 Novel substituted sulfoximine compounds

Publications (2)

Publication Number Publication Date
US20200140382A1 US20200140382A1 (en) 2020-05-07
US11236045B2 true US11236045B2 (en) 2022-02-01

Family

ID=62873500

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/617,389 Expired - Fee Related US11236045B2 (en) 2017-06-09 2018-06-08 Substituted sulfoximine compounds

Country Status (3)

Country Link
US (1) US11236045B2 (en)
EP (1) EP3634951B8 (en)
WO (1) WO2018225018A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234245B2 (en) 2018-07-20 2025-02-25 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117209447A (en) 2017-07-24 2023-12-12 诺华股份有限公司 Compounds and compositions for treating disorders associated with NLRP activity
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
PE20200758A1 (en) 2017-08-15 2020-07-27 Inflazome Ltd SULFONYLUREAS AND SULFONYLTIOUREAS AS INHIBITORS OF NLRP3
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited Novel compounds
PE20211333A1 (en) 2018-08-15 2021-07-22 Inflazome Ltd NOVEL SULFONAMIDAUREA COMPOUNDS
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
ES2974842T3 (en) 2018-11-13 2024-07-01 Novartis Ag Compounds and compositions for the treatment of conditions associated with nlrp activity
US12134611B2 (en) 2018-11-13 2024-11-05 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
US20230051589A1 (en) * 2018-11-16 2023-02-16 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
CN113474333B (en) * 2019-01-14 2025-06-13 载度思生命科学有限公司 New substituted sulfonylurea derivatives
WO2020154321A1 (en) 2019-01-22 2020-07-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
WO2020154499A1 (en) 2019-01-23 2020-07-30 Novartis Inflammasome Research, Inc. Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
SG11202107653RA (en) * 2019-01-25 2021-08-30 Nodthera Ltd Carbamate derivatives and uses thereof
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
EP3983388A1 (en) * 2019-06-12 2022-04-20 Nodthera Limited Sulfonamide derivatives and uses thereof
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
EP4013762A1 (en) 2019-08-16 2022-06-22 Inflazome Limited Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
JP2022545400A (en) 2019-08-16 2022-10-27 インフレイゾーム リミテッド Macrocyclic Sulfonylurea Derivatives Useful as NLRP3 Inhibitors
JP2022547882A (en) 2019-09-06 2022-11-16 インフレイゾーム リミテッド NLRP3 inhibitor
EP4027986A4 (en) 2019-09-12 2023-10-04 Zydus Lifesciences Limited NEW SUBSTITUTED SULFOXIMINE DERIVATIVES
WO2021150574A1 (en) * 2020-01-22 2021-07-29 Genentech, Inc. Sulfonimidamide compounds as nlrp3 modulators
JP2023513935A (en) 2020-02-18 2023-04-04 インフレイゾーム リミテッド Compound
WO2021171230A1 (en) * 2020-02-28 2021-09-02 Cadila Healthcare Limited Novel substituted sulfonylurea and sulfoximineurea derivatives
CN113717087A (en) * 2020-05-26 2021-11-30 瑞博(杭州)医药科技有限公司 Preparation method of deoxidation fluorination reagent
CA3178361A1 (en) 2020-06-19 2021-12-23 Emanuele Gabellieri Dihydrooxazole and thiourea derivatives modulating the nlrp3 inflammasome pathway
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
US20250109126A1 (en) 2021-12-22 2025-04-03 Ac Immune Sa Dihydro-oxazol derivative compounds
JP2025524640A (en) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
CN119998284A (en) 2022-07-28 2025-05-13 Ac免疫有限公司 New compounds
EP4673427A1 (en) * 2023-03-02 2026-01-07 Zydus Lifesciences Limited Treatment for inflammatory bowel disease
WO2025133307A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Heterocyclic modulators of the nlrp3 inflammasome pathway
TW202545527A (en) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3 and glp-1a combination therapies
WO2025153625A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) 2024-01-17 2025-07-24 Ac Immune Sa Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666506A (en) 1984-08-08 1987-05-19 E. I. Du Pont De Nemours And Company Herbicidal pyrimidines
US5258406A (en) * 1991-12-20 1993-11-02 Eli Lilly And Company Sulfonimidamides
WO1998032733A1 (en) 1997-01-29 1998-07-30 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US20020077486A1 (en) 2000-02-04 2002-06-20 Scarborough Robert M. Platelet ADP receptor inhibitors
WO2016131098A1 (en) 2015-02-16 2016-08-25 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2019023147A1 (en) 2017-07-24 2019-01-31 IFM Tre, Inc. Compounds and compositions for treating conditions associated with nlrp activity
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited Novel compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383026A1 (en) 1999-09-14 2001-03-22 Pfizer Products Inc. Combination treatment with il-1ra and compounds that inhibit il-1 processing and release
WO2014190015A1 (en) 2013-05-21 2014-11-27 Virginia Commonwealth University Cryopyrin inhibitors for preventing and treating inflammation
WO2016123229A1 (en) 2015-01-29 2016-08-04 Yale University Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders
GB201513481D0 (en) 2015-07-30 2015-09-16 Univ Manchester Inhibitor compounds
US10195170B2 (en) 2015-08-17 2019-02-05 Twi Biotechnology, Inc. Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs
CN109196118A (en) 2015-11-04 2019-01-11 艾德拉药物股份有限公司 Composition for inhibiting NLRP3 gene expression and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666506A (en) 1984-08-08 1987-05-19 E. I. Du Pont De Nemours And Company Herbicidal pyrimidines
US5258406A (en) * 1991-12-20 1993-11-02 Eli Lilly And Company Sulfonimidamides
WO1998032733A1 (en) 1997-01-29 1998-07-30 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US20020077486A1 (en) 2000-02-04 2002-06-20 Scarborough Robert M. Platelet ADP receptor inhibitors
WO2016131098A1 (en) 2015-02-16 2016-08-25 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2019023147A1 (en) 2017-07-24 2019-01-31 IFM Tre, Inc. Compounds and compositions for treating conditions associated with nlrp activity
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited Novel compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Database PubChem Compound [Online], XP002783838, retrieved from NCBI Database accession No. 10787134 compound 10787134, Oct. 26, 2006.
DATABASE PucChem Compound [online] 26 October 2006 (2006-10-26), XP002783838, retrieved from NCBI
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 June 2008 (2008-06-13), XP002783839, retrieved from STN
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Jun. 13, 2008, XP002783839, retrieved from STN Database accession No. 1027831-60-2 compounds 1027831-60-2.
European Patent Office, Munich, International Preliminary Report on Patentability, dated Jul. 25, 2019, PCT/IB2018/054134.
European Patent Office, Third Party Observation for application No. EP20180739634, Filed Sep. 8, 2021, Transmitted to Applicant on Sep. 20, 2021, Munich, Germany.
Toth J. E. et al, Sulfonimidamide Analogs of Oncolytic Sulfonylureas, Journal of Medicinal Chemistry, 1997, pp. 1018-1025, vol. 40, No. 6.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12234245B2 (en) 2018-07-20 2025-02-25 Genentech, Inc. Sulfonimidamide compounds as inhibitors of interleukin-1 activity

Also Published As

Publication number Publication date
EP3634951B1 (en) 2024-07-10
WO2018225018A1 (en) 2018-12-13
EP3634951B8 (en) 2024-08-21
US20200140382A1 (en) 2020-05-07
EP3634951A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
US11236045B2 (en) Substituted sulfoximine compounds
WO2019043610A1 (en) Novel substituted sulfonylurea derivatives
US10786494B2 (en) CCR6 compounds
US12084416B2 (en) Substituted sulfonylurea derivatives
CA3005656A1 (en) Oxoisoindolinyl compounds as modulators of chemokine receptors
US20230096220A1 (en) Novel subtituted sulfonylurea and sulfoximineurea derivatives
NO323395B1 (en) Substituted glutarimides which are inhibitors of IL-12 production, process for their preparation, use thereof, and drugs containing the compounds.
JP2004509855A (en) Coumarin derivatives useful as TNFα inhibitors
US12377070B2 (en) Substituted sulfoximine derivatives
HRP20010135A2 (en) Novel natural product derivatives
US7101873B2 (en) Pyrimidinedione derivatives
HK40077009A (en) Novel substituted sulfoximine derivatives
HK40081478A (en) Novel substituted sulfonylurea and sulfoximineurea derivatives
HK40056657A (en) Novel substituted sulfonylurea derivatives
HK40056657B (en) Novel substituted sulfonylurea derivatives
HK1229729A1 (en) Ccr6 compounds
JPH01149784A (en) 4h-quinolidin-4-one derivative

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: CADILA HEALTHCARE LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHARMA, RAJIV;IYER, PRAVIN;AGARWAL, SAMEER;SIGNING DATES FROM 20200108 TO 20200115;REEL/FRAME:053193/0384

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362